SHH Holoprosencephaly Spectrum — Comprehensive Research Report

1. Disease Information

Overview. Holoprosencephaly (HPE) is the most common structural malformation of the developing human forebrain (prosencephalon), arising from failure of the prosencephalon to divide into distinct cerebral hemispheres and underlying deep-brain (diencephalic) structures during the third to fourth week of gestation. It exists as a continuous phenotypic spectrum — from the most severe form (alobar HPE with a single fused monoventricle and cyclopia) through semilobar and lobar forms to "microform" HPE, in which craniofacial midline anomalies (e.g., a single central maxillary incisor, hypotelorism) occur with an essentially normal-appearing brain on imaging (GeneReviews Holoprosencephaly Overview; Holoprosencephaly: Review of Embryology, Clinical Phenotypes, Etiology and Management, PMC10137117). "SHH Holoprosencephaly Spectrum" designates the subset of the HPE spectrum attributable to heterozygous pathogenic variation in the SHH (Sonic Hedgehog) gene at 7q36.3 — the single most common identified monogenic cause of nonsyndromic HPE — and, more broadly, the mechanistic spectrum of disease produced by disruption anywhere along the SHH signal-transduction pathway (ligand, receptors, intracellular transducers, and transcriptional effectors).

Key identifiers: - OMIM: Holoprosencephaly 1 (HPE1, chromosomal/locus designation) #236100; Holoprosencephaly 3 (HPE3, the SHH-specific disorder) #142945; SHH gene entry 600725 (OMIM 236100; OMIM 142945) - MONDO: MONDO:0016296 (holoprosencephaly, general); MONDO:0012322 (holoprosencephaly 5/ZIC2, illustrating the per-gene MONDO subtyping pattern) (Monarch Initiative) - Orphanet: ORPHA:2162 (Holoprosencephaly) (Orphanet) - ICD-10: Q04.2 (Holoprosencephaly); ICD-11: LA02.0 - MeSH: D019204 (Holoprosencephaly) - HGNC gene:* SHH, HGNC:10848, chromosome 7q36.3

Synonyms: Arhinencephaly (older, imprecise term); HPE; "cyclopia" (for the most severe alobar phenotype); Holoprosencephaly-3 (HPE3, SHH-specific OMIM designation); Autosomal Dominant Holoprosencephaly (ADHPE, when referring to the SHH/ZIC2/SIX3/TGIF1 nonsyndromic group).

Data provenance. Most of the mechanistic and epidemiologic knowledge base for SHH-HPE is aggregated disease-level data: large multicenter case series and mutation-spectrum studies (Cohen, Roessler/Muenke, Solomon et al.), population birth-defects surveillance registries, and animal-model experimental data, rather than large-scale individual-patient EHR cohorts. GeneReviews and Orphanet function as the principal curated aggregating clinical-genetics resources; ClinVar/ClinGen aggregate individual-variant-level clinical data.

2. Etiology

Disease-causal framework. HPE is fundamentally a disorder of Sonic Hedgehog (SHH) signaling failure in the rostral neural plate/prosencephalon, producing inadequate ventral midline induction and incomplete telencephalic cleavage. "Disruption of sonic hedgehog (SHH) signaling is the main pathophysiologic mechanism underlying HPE. SHH is a secreted protein that has a key role in the maintenance of the notochord and the patterning and induction of the ventral forebrain" (Holoprosencephaly Overview, GeneReviews). Causation is multifactorial and heterogeneous, spanning chromosomal, monogenic, environmental/teratogenic, and — very often — combined ("multiple-hit") mechanisms in a single individual.

Genetic risk factors

• Chromosomal abnormalities account for roughly 25–50% of all HPE cases. Trisomy 13 (Patau syndrome) is the single most common chromosomal cause, comprising ~40–75% of chromosomally abnormal HPE depending on the series; trisomy 18 and triploidy are also recurrent (PMC10137117).
• Copy-number variants (CNVs) are found in ~10–14% of HPE cases, frequently overlapping known HPE-gene loci (e.g., 18p11.3/TGIF1, 2p21/SIX3, 13q32/ZIC2).
• Monogenic (single-gene) causes account for ~18–25% of cases. At least 17 non-syndromic HPE genes are recognized, virtually all functioning within or regulating the SHH pathway:
• SHH (7q36.3) — the most common single-gene cause, 5.4–5.9% of non-syndromic HPE (PMC10137117); in specific ascertainment strata, SHH mutations were found in "3.7% of sporadic cases, 18% of familial cases, and 37% of families with autosomal dominant transmission" (Mutational Spectrum of the Sonic Hedgehog Gene, Hum Mol Genet 1999).
• ZIC2 (13q32) — 4.8–5.2%, predominantly de novo (70–80%), distinctive facial gestalt.
• SIX3 (2p21), a direct transcriptional regulator of SHH expression — ~3%, associated with more severe HPE subtypes.
• GLI2 (2q14.2) — ~3.2%, often associated with microforms and pituitary anomalies.
• TGIF1 (18p11.3) — <1%.
• Additional/rarer genes acting within the pathway: PTCH1 (the SHH receptor), CDON, GAS1, DISP1, FGF8, FGFR1, DLL1, NODAL, FOXH1 (PMC10137117; Monarch Initiative).
• Rare non-dominant modes: autosomal recessive HPE (STIL), and X-linked HPE (STAG2, SMC1A — all reported probands female, suggesting male lethality).
• Modifier / second-site (oligogenic) loci: GAS1 functions as a genetic modifier of SHH-pathway HPE — "loss of a single Shh allele in a Gas1−/− background significantly exacerbated the midline craniofacial phenotype, providing genetic evidence that Shh and Gas1 interact," and hypomorphic GAS1 alleles are proposed to contribute to phenotypic variability in patients carrying primary mutations in other HPE genes, consistent with a "multiple-hit hypothesis" (Gas1 is a modifier for holoprosencephaly, J Clin Invest 2007, PMID:17525797). GAS1 maps to 9q21.3–q22.

Environmental / non-genetic risk factors

• Maternal pre-gestational (insulin-requiring) diabetes mellitus is the best-established environmental risk factor, conferring >10-fold increased risk; HPE occurs in ~1–2% of infants of diabetic mothers. Proposed mechanisms include hyperglycemia-driven oxidative free-radical injury, apoptosis, and impaired cranial neural crest cell migration (PMC10137117).
• Maternal alcohol consumption during pregnancy is dose-associated with increased HPE risk; ethanol is proposed to directly inhibit hedgehog protein cholesterol modification and SHH autoprocessing/signaling. Gene–environment interaction is well documented in the mouse: "the teratogenic effects of prenatal ethanol exposure are exacerbated by Sonic Hedgehog or Gli2 haploinsufficiency" (PMC3929747).
• Retinoic acid exposure, mycotoxins (ochratoxins), and pharmacologic/dietary cholesterol-synthesis inhibitors are implicated teratogens; heavy metals and ionizing radiation have been proposed but are not definitively established.
• Maternal folic acid intake has been reported as potentially protective (one study reporting a 73% risk reduction with periconceptional use), though evidence is mixed across studies.

Gene–environment interaction

The clearest documented gene–environment interaction is between SHH-pathway haploinsufficiency and ethanol exposure: mice heterozygous for null alleles of Shh or Gli2 show markedly exacerbated HPE-spectrum phenotypes upon prenatal ethanol exposure compared with either insult alone, directly modeling the "multiple-hit" (genetic susceptibility + teratogen) hypothesis proposed for human HPE, including the Cdon-mutant/ethanol interaction rescued by reduced Ptch1 dosage (PMC3823703). This supports a threshold/dosage model in which partial SHH pathway function from a single mutant allele is pushed below the pathogenic threshold by an independent environmental insult on the wild-type allele's output.

Suggested GO/pathway terms: GO:0007224 (smoothened signaling pathway), GO:0007228 (positive regulation of hh target transcription factor activity), GO:0021537 (telencephalon development), GO:0021782 (glial cell development — ventral forebrain patterning downstream processes).

3. Phenotypes

Phenotype severity in SHH-HPE forms a continuum correlating loosely (not strictly) with genotype, with extreme intrafamilial variability — "ranging from alobar HPE with cyclopia to clinically normal" even within a single kindred carrying an identical SHH variant (GeneReviews).

Structural brain (clinical signs, neuroimaging)

Craniofacial (symptoms/signs) — severity-graded

• Cyclopia (HP:0000531) / synophthalmia (HP:0000577): single/fused midline eye, alobar HPE.
• Ethmocephaly (extreme hypotelorism with absent nose and proboscis) and cebocephaly (single-nostril flattened nose) — severe/intermediate forms.
• Hypotelorism (HP:0000601), midline cleft lip/palate (HP:0000175/HP:0000176), premaxillary agenesis.
• Microform features (mild end of spectrum, may occur with normal-appearing brain): single central maxillary incisor / solitary median maxillary central incisor (SMMCI) (HP:0006315) — a distinctive marker of autosomal dominant (often SHH-related) HPE, estimated general-population incidence ~1:50,000; hypotelorism, anosmia/hyposmia (HP:0004408, from absent olfactory tracts/bulbs), depressed nasal ridge. A specific missense variant, SHH p.Ile111Phe, has been reported as potentially SMMCI-specific (SMMCI syndrome, PMC1464380).

Neurodevelopmental / behavioral

• Developmental delay/intellectual disability (HP:0001263) — present in virtually all individuals with structural HPE; severity correlates with brain malformation grade.
• Spasticity (HP:0001257), axial hypotonia (HP:0008936), dystonia/choreoathetosis (correlating with basal ganglia non-separation).
• Seizures (HP:0001250) — present in ~50% of HPE patients, without strict correlation to HPE severity; often anticonvulsant-responsive but can be refractory when cortical dysplasia coexists.
• In higher-functioning (typically microform/lobar) individuals: executive dysfunction, ADHD, learning disabilities, anxiety, depression.

Laboratory / endocrine abnormalities

• Central diabetes insipidus (HP:0000873) — the single most common endocrinopathy, occurring in ~70% of patients with classic (structural) HPE, correlating with severity of hypothalamic non-separation.
• Hypothyroidism (HP:0000821) ~11%, hypoadrenocorticism/ACTH deficiency (HP:0000829) ~7%, growth hormone deficiency (HP:0000824) ~5% (Endocrine disorders associated with holoprosencephaly, PMID:16355806).

Onset, severity, progression, frequency

• Onset: congenital/prenatal by definition (embryonic weeks 3–4); microform features may not be recognized clinically until later childhood or in an "unaffected" relative investigated after a severely affected proband is identified.
• Severity/course: structural brain phenotype itself is static (a developmental field defect, not degenerative), but the clinical picture "progresses" developmentally — feeding difficulties, seizures, and movement disorders often emerge/are recognized over the first years of life. Endocrine, orthopedic (contractures, scoliosis, hip dislocation), and gastrointestinal complications accrue over time and require longitudinal management.
• Quality of life: severely impacted in alobar/semilobar HPE (profound motor and cognitive impairment, ~60% of adolescent/adult survivors nonambulatory/nonverbal); comparatively preserved in microform/lobar/MIHV HPE, where individuals may be independently ambulatory, verbal, and in some cases of documented normal intelligence despite carrying an SHH pathogenic variant.

4. Genetic / Molecular Information

Primary causal gene: SHH (HGNC:10848, chromosome 7q36.3, OMIM 600725), encoding the secreted morphogen Sonic Hedgehog. Heterozygous pathogenic variants cause Holoprosencephaly-3 (HPE3, OMIM #142945)*.

Variant spectrum and classification: - Reported variant classes span "amino-acid substitutions, insertion/deletion mutations, frame-shift mutations, poly-alanine tract expansions, and gene deletions" throughout the gene (Clinical Utility Gene Card, PMC3039493). - The dominant molecular mechanism is loss of function / haploinsufficiency: "numerous different heterozygous mutations have been identified in HPE patients and include missense, nonsense, deletion, and frameshift mutations... predicted to cause loss-of-function through either key structural alterations of the ligand or its altered synthesis" (Mutational spectrum studies, ResearchGate summary). - Genotype–phenotype correlation is imperfect but present in aggregate: truncating variants are more likely to produce frank structural HPE than non-truncating (missense) variants, though a substantial fraction of missense variants also cause severe disease and truncating variants can occur in essentially unaffected carriers — reflecting the pathway's extreme sensitivity to dosage and its dependence on genetic/environmental modifiers. - ACMG/AMP classification: SHH variants curated in ClinVar and by ClinGen are predominantly classified pathogenic/likely pathogenic when truncating and located in functionally critical (N-terminal signaling) domains; missense VUS classification is common given incomplete penetrance and variable expressivity, complicating variant interpretation. ClinGen's Gene Dosage curation supports haploinsufficiency (dosage sensitivity) for SHH (ClinGen SHH Dosage). - De novo rate: approximately 10–30% of SHH pathogenic variants arise de novo; the remainder are inherited from a heterozygous, often clinically unaffected or minimally affected (reduced penetrance), parent. - Population frequency: SHH loss-of-function variants are constrained in population databases (gnomAD) consistent with dominant haploinsufficiency, though exact pLI/constraint metrics were not independently retrieved in this pass — curators should verify current gnomAD constraint scores directly.

Related monogenic/HPE-pathway genes (for the broader "SHH pathway" spectrum): PTCH1 (SHH receptor, negative regulator of SMO), SMO (downstream transducer — also implicated in SMMCI via an SMO variant), GLI2/GLI1/GLI3 (downstream zinc-finger transcription effectors — GLI2 acts as activator or repressor depending on pathway state), CDON and GAS1 (co-receptors/modifiers), DISP1 (dispatched homolog 1, required for SHH ligand release), FGF8/FGFR1, ZIC2, SIX3, TGIF1, NODAL, FOXH1.

Somatic vs germline: HPE-causing SHH variants are germline; SHH pathway somatic mutations (PTCH1, SMO, GLI activating variants) are separately implicated in medulloblastoma and basal cell carcinoma — a mechanistically related but clinically distinct disease process (oncogenic SHH-pathway activation vs. developmental SHH-pathway loss-of-function).

Epigenetics: Not well characterized specifically for SHH-HPE; the SHH pathway more broadly is subject to epigenetic regulation of its target-gene program (Gli-binding sites, cis-regulatory element methylation) but no HPE-specific epigenetic biomarker is established.

Chromosomal abnormalities: As above — trisomy 13, trisomy 18, triploidy; CNVs overlapping 7q36 (deletions encompassing SHH or its long-range cis-regulatory elements, e.g., the ZRS-like forebrain enhancers) can also produce HPE3-equivalent phenotypes and are detectable by chromosomal microarray (CMA), which identifies pathogenic CNVs in ~10% of HPE cases.

Suggested ontology terms: HGNC:10848 (SHH); GO:0005113 (patched binding); GO:0030177 (positive regulation of Wnt signaling pathway, cross-talk); UniProt P08151 (mouse Shh)/Q15465 (human SHH protein).

5. Environmental Information

(Overlaps with §2 but detailed here per template.)

• Toxins/teratogens: Cyclopamine and related Veratrum californicum steroidal jerveratrum alkaloids are the classic experimental HPE teratogens (see §14/§15) and act as direct pharmacologic SMO antagonists — a mechanistic proof-of-concept for pathway-level causation in humans.
• Maternal metabolic factors: Pregestational diabetes (strongest established environmental risk factor, >10-fold risk elevation), maternal obesity has been suggested in some epidemiologic series.
• Lifestyle factors: Maternal alcohol use (dose-related), tobacco use has been investigated with less consistent association; retinoic acid/vitamin A excess.
• Infectious agents: No well-established infectious cause of HPE; unlike some other CNS malformations (e.g., congenital Zika microcephaly), HPE is not primarily an infectious-teratogen disease, though isolated case reports of maternal infection coinciding with HPE exist without established causality.
• Nutritional: Low periconceptional folate has been proposed as a risk factor and supplementation as potentially protective, though data are less robust than for neural tube defects.

6. Mechanism / Pathophysiology

Causal chain (trigger → clinical manifestation):

1. Molecular trigger: Heterozygous loss-of-function variant in SHH (or another pathway gene) reduces the dose/gradient of functional SHH ligand available to the ventral prosencephalic midline and prechordal plate/notochord signaling centers during gastrulation and early neurulation (approximately days 18–28 of human gestation).
2. Cellular/tissue-level consequence: Insufficient SHH-PTCH1-SMO-GLI signal transduction in the ventral neural tube and rostral neural plate fails to specify ventral forebrain identity and fails to antagonize dorsalizing BMP/WNT signals adequately — "development of the forebrain critically depends on the Sonic Hedgehog (Shh) signaling pathway... regulating processes such as ventral forebrain neuronal differentiation" (Frontiers in Molecular Biosciences, 2021).
3. Morphogenetic consequence: Failure of the prosencephalon to cleave sagittally into paired cerebral hemispheres and to separate horizontally into telencephalon/diencephalon, and failure of the underlying paired basal ganglia, thalami, and hypothalamus to individuate — producing the alobar/semilobar/lobar continuum of structural brain malformation.
4. Coupled craniofacial consequence: Because cranial neural crest cell migration and facial primordia patterning are co-regulated by the same rostral midline SHH signaling center, forebrain and facial anomalies are mechanistically coupled ("the face predicts the brain") — hence the correlation (though imperfect) between craniofacial severity and CNS malformation severity.
5. Downstream systemic consequences: Hypothalamic-pituitary axis maldevelopment (from disrupted ventral diencephalic/infundibular patterning) → central diabetes insipidus and anterior pituitary hormone deficiencies; abnormal olfactory bulb/tract formation → anosmia; cortical/white-matter maldevelopment and basal ganglia non-separation → developmental delay, spasticity, dystonia, seizures.

Molecular pathway detail (canonical Hedgehog signal transduction): - In the absence of SHH ligand, PTCH1 (the receptor) tonically inhibits SMO (Smoothened, a GPCR-family transducer). - SHH ligand binding to PTCH1 relieves this inhibition, permitting SMO to translocate/accumulate in the primary cilium. - Active SMO antagonizes PKA-mediated phosphorylation/proteolytic processing of the GLI2/GLI3 transcription factors, shifting them from truncated transcriptional repressor forms (GLIR) to full-length activator forms (GLIA), and inducing GLI1 as a downstream amplifying activator (Role of Sonic Hedgehog in HPE and SRPS, PMC8468456). - This canonical pathway is strictly primary-cilium-dependent in vertebrates; non-canonical, cilium-independent SHH signaling also exists. - Modifiers/co-receptors CDON and GAS1 enhance ligand-receptor engagement and pathway sensitivity, explaining their role as dose-dependent genetic modifiers of HPE penetrance.

Threshold/dosage model & variable expressivity: HPE is understood as a classic dosage-sensitive developmental threshold disorder — total pathway output (from SHH ligand concentration, receptor/co-receptor availability, and downstream transducer dose) must exceed a minimum level for normal ventral forebrain patterning; any combination of genetic (primary mutation + modifier alleles, potentially oligogenic "multiple-hit" combinations) and environmental (ethanol, cholesterol-synthesis disruption) insults that additively reduces net pathway output below this threshold produces disease, with severity scaling to the degree of shortfall. This directly explains the extreme intrafamilial phenotypic variability characteristic of SHH-HPE — "temporal disruption of a single molecular pathway can produce variable expressivity" and "temporal perturbations in sonic hedgehog signaling elicit the [full] spectrum of holoprosencephaly phenotypes" (JCI, PMID referenced via search).

Cell types involved (CL terms suggested): notochord cells, prechordal plate mesendoderm, ventral neural tube floor-plate cells (CL:0000030 glioblast/floor plate neuroepithelium), cranial neural crest cells (CL:0000333), telencephalic ventricular zone progenitors, radial glia.

GO biological process terms: GO:0007224 (smoothened signaling pathway), GO:0021998 (neural plate mediolateral regionalization), GO:0021801 (cerebral cortex radial glia guided migration — downstream), GO:0021537 (telencephalon development), GO:0060021 (roof plate formation — dorsal midline, indirectly perturbed by ectopic ventral signaling).

Omics/advanced technologies: Single-cell and spatial transcriptomic characterization of SHH-gradient-dependent ventral forebrain progenitor domains has been performed extensively in mouse and, more recently, in human forebrain organoid models, though HPE-specific patient-derived organoid/iPSC transcriptomic datasets are still relatively sparse in the literature compared with the extensive classical mouse genetic literature.

7. Anatomical Structures Affected

Organ level (primary): Brain — specifically prosencephalon-derived structures: cerebral hemispheres/telencephalon, diencephalon (thalamus, hypothalamus), pituitary gland (hypophysis), olfactory bulbs/tracts. UBERON terms: UBERON:0001890 (forebrain), UBERON:0002435 (striatum/basal ganglia), UBERON:0001898 (hypothalamus), UBERON:0000007 (pituitary gland), UBERON:0002264 (olfactory bulb).

Organ level (secondary/associated): craniofacial skeleton and soft tissue (midface, nose, maxilla, orbits) — UBERON:0000209 (midface), UBERON:0002397 (nose), UBERON:0000966 (retina/eye structures in cyclopia/synophthalmia); gastrointestinal tract (motility dysfunction, reflux); musculoskeletal system (contractures, scoliosis, hip dysplasia secondary to spasticity).

Body systems involved: nervous system (primary), endocrine system (hypothalamic-pituitary axis), craniofacial/skeletal system, gastrointestinal system (secondary, functional), sensory systems (olfactory, visual).

Tissue/cell level: neuroepithelium of the ventral neural tube and prosencephalic vesicle; cranial neural crest-derived mesenchyme of the face; notochord and prechordal plate (signaling source tissues, transiently present embryonic structures).

Subcellular level (GO Cellular Component): primary cilium (GO:0005929) — obligate site of canonical vertebrate Hedgehog pathway transduction; plasma membrane (PTCH1/SMO localization); nucleus (GLI transcription factor activity).

Localization/laterality: HPE is fundamentally a midline developmental field defect; laterality is not typically a feature (bilateral/symmetric midline non-separation), though craniofacial anomalies can show asymmetric severity.

8. Temporal Development

• Onset: Congenital/embryonic — the primary morphogenetic lesion occurs during the third–fourth week of gestation (Carnegie stages 8–13), i.e., before most pregnancies are clinically recognized. Clinical recognition, however, ranges from first-trimester prenatal ultrasound (severe forms) to incidental discovery in adulthood (microform HPE in an unaffected-appearing relative of a proband).
• Onset pattern: The structural malformation itself is a single embryonic developmental event (not acute/subacute in the postnatal sense); it is congenital and, at the anatomic level, non-progressive.
• Disease stages/progression: Anatomically static once formed, but the clinical course is one of evolving multisystem complications over infancy and childhood: emergence of seizures, feeding/aspiration issues, movement disorders, and endocrinopathies (diabetes insipidus, hypopituitarism) typically become apparent and require intervention over the first months to years of life. In milder (lobar/MIHV/microform) cases, diagnosis is sometimes delayed until developmental delay, seizures, or a movement disorder prompts neuroimaging later in childhood.
• Course pattern: Chronic, lifelong, non-remitting (a static structural malformation with a dynamic, generally stable-to-slowly-evolving functional/complications profile); not relapsing-remitting.
• Critical developmental window: The teratogenic/mutational critical period is narrow — gestational days ~18–28 in humans (directly paralleling the day-13–14 post-conception critical window identified for cyclopamine-induced HPE in sheep).

9. Inheritance and Population

Epidemiology: - Conceptus prevalence: ~1:250 (i.e., extremely common among all conceptuses). - Live-birth prevalence: ~1:8,000–1:16,000, reflecting massive fetal loss (spontaneous abortion) of severely affected conceptuses between conception and term (PMC10137117). - Regional Orphanet-cited birth prevalence figures: 1–5/10,000 in Europe and Latin America; 6–9/10,000 in Taiwan; >1/1,000 reported in Japan (Orphanet).

Inheritance pattern (for nonsyndromic/SHH-pathway HPE): Autosomal dominant with markedly incomplete penetrance and extremely variable expressivity — the hallmark genetic feature of this disorder. "Only about one-third of SHH pathogenic-variant carriers develop overt HPE," with the remainder showing microforms or apparently normal phenotype (PMC10137117). Rare autosomal recessive (STIL) and X-linked (STAG2, SMC1A) forms exist for specific genes outside the core SHH/ZIC2/SIX3/TGIF1 group.

Penetrance: Incomplete; empiric sibling recurrence data (from GeneReviews) for a parent known to carry a pathogenic variant: approximately 20% risk of overt HPE, 15% risk of microform-only phenotype, and 15% chance of apparently normal phenotype in offspring who inherit the variant — figures that must be communicated carefully in genetic counseling given their inherent imprecision.

Expressivity: Highly variable, both between and within families; documented range from cyclopia/alobar HPE to an entirely normal-appearing, sometimes "intellectually gifted," carrier relative.

Genetic anticipation: Not a recognized feature of SHH-HPE (not a repeat-expansion disorder).

Germline mosaicism: Documented in some HPE families, an important consideration when counseling apparently non-mosaic, phenotypically normal parents of a de novo-appearing proband — recurrence risk is not zero even when parental testing is negative.

Founder effects / consanguinity: No major SHH-specific founder mutation is broadly established in the literature reviewed here; consanguinity is more relevant to the rare autosomal recessive causes of syndromic HPE (e.g., Smith-Lemli-Opitz syndrome, DHCR7) than to dominant SHH-pathway HPE.

Carrier frequency: Not meaningfully defined for a dominant, highly penetrant-when-severe disorder in the way it is for recessive conditions; population allele frequency of SHH loss-of-function variants is expected to be very low given strong purifying selection (dosage sensitivity/haploinsufficiency).

Population demographics: No strong, consistently replicated ethnic/geographic predilection for SHH-specific HPE beyond the population-level birth-prevalence variation noted above (with Japan and Taiwan reporting higher observed birth prevalence than Europe/Latin America — the reasons for this variation, whether ascertainment, environmental, or genetic-background related, are not firmly established in the sources reviewed). Sex ratio: No strong sex bias is established for autosomal dominant SHH-pathway HPE (in contrast to the rare X-linked forms, where affected probands are exclusively female, consistent with presumed male lethality).

10. Diagnostics

Clinical/imaging tests: - Prenatal ultrasound: can detect severe (alobar, semilobar) HPE from the first trimester, showing absent interhemispheric fissure, fused/distorted choroid plexuses, fused thalami, and midline facial anomalies; the "snake under the skull" Doppler sign (anterior displacement of the anterior cerebral artery beneath the frontal bone) supports a diagnosis of mild lobar HPE. Milder forms are frequently missed prenatally. - Fetal MRI: second-line confirmatory study for suspected cases. - Postnatal MRI is the imaging modality of choice for definitive subtype classification and detection of associated anomalies; interpretation by a reviewer experienced with HPE subtyping is important to avoid misclassifying related-but-distinct entities (isolated callosal dysgenesis, arrhinencephaly, isolated pituitary dysgenesis) as HPE.

Genetic testing (recommended sequential approach, per GeneReviews): 1. Chromosome analysis — karyotype (if trisomy 13/18/triploidy is suspected clinically) and/or chromosomal microarray (CMA) (detects pathogenic CNVs in ~10% of cases). 2. Multigene HPE panel at minimum including SHH, ZIC2, SIX3 (± TGIF1, GLI2, PTCH1, CDON, FGF8, FGFR1, DISP1, others). 3. Exome sequencing (± exome-based CNV/array analysis for multiexon deletions/duplications) if panel testing is non-diagnostic — a recent exome study cited a 22% diagnostic yield in previously unresolved cases. 4. Targeted single-gene sequencing when a specific syndromic diagnosis (e.g., Smith-Lemli-Opitz) is clinically suspected.

Biochemical/laboratory testing: For suspected Smith-Lemli-Opitz syndrome (a key syndromic HPE differential), elevated 7-dehydrocholesterol / reduced cholesterol on sterol analysis supports the diagnosis pending DHCR7 sequencing.

Differential diagnosis: - Chromosomal HPE (trisomy 13 — the single most common overall cause of the HPE phenotype). - Syndromic monogenic HPE: Smith-Lemli-Opitz syndrome (DHCR7, cholesterol-synthesis defect), Kallmann syndrome type 2 / FGFR1-related disorders (including Hartsfield syndrome: HPE + ectrodactyly + cleft lip/palate), Steinfeld syndrome (CDON), Stromme syndrome (CENPF, ciliopathy), CNOT1-related (Vissers-Bodmer) syndrome. - Other non-HPE midline brain malformations that can be misdiagnosed as HPE (isolated septo-optic dysplasia, isolated agenesis of the corpus callosum, isolated arrhinencephaly) — correct subtyping is important since recurrence-risk counseling differs substantially.

Screening: No population-based newborn screening exists for HPE (it is a structural malformation, not a metabolic disorder detectable on standard newborn screening panels). Once a familial pathogenic variant is identified, prenatal diagnosis (chorionic villus sampling/amniocentesis for targeted variant testing) and preimplantation genetic testing (PGT) are available and have been reported in the literature, including an early NEJM report of preimplantation diagnosis for a familial SHH mutation (NEJM 2003).

11. Outcome / Prognosis

Survival/mortality (aggregate HPE-spectrum data): - 24-hour mortality: ~33% across all HPE subtypes combined. - 1-month mortality: ~58%. - 1-year survival: ~29% overall (heavily weighted by the most severe alobar cases; survival is substantially better in lobar/MIHV/microform disease). - Non-syndromic, euploid (normal-karyotype) HPE has meaningfully better survival than syndromic or chromosomally abnormal HPE. - A described cohort of surviving adolescents/adults was ~50% semilobar variant, reflecting improved long-term survival in less severe subtypes with modern diagnostic and supportive care (PMC10137117).

Morbidity/function: - Developmental delay is present in virtually all individuals with structural (imaging-positive) HPE, though severity spans from profound (alobar) to comparatively mild (lobar/MIHV). - Approximately 60% of adolescent/adult alobar/semilobar survivors are non-ambulatory and non-verbal with severe global impairment. - Milder (lobar, MIHV) forms permit independent or assisted ambulation and, in some cases, functional speech; individuals are more often diagnosed later, upon emergence of developmental delay, seizures, or a movement disorder rather than at birth.

Complications: hydrocephalus (16–40%), refractory or well-controlled seizures (~50% of cases), central diabetes insipidus (~70% of classic/structural HPE), anterior hypopituitarism (5–10%), feeding dysfunction/aspiration risk (majority of alobar/semilobar patients require gastrostomy), gastroesophageal reflux, spasticity/dystonia-related orthopedic complications (contractures, hip dislocation, scoliosis).

Prognostic factors: HPE subtype/severity grade (alobar > semilobar > lobar/MIHV > microform) is the dominant prognostic determinant; euploidy vs. chromosomal/syndromic etiology; presence/absence of hydrocephalus; degree of hypothalamic non-separation (correlates with diabetes insipidus severity).

12. Treatment

There is no disease-modifying or curative therapy for SHH-HPE; management is exclusively supportive, multidisciplinary, and complication-directed.

Pharmacotherapy (symptomatic/supportive): - Desmopressin acetate (synthetic vasopressin analog) for central diabetes insipidus — "the treatment of choice," typically dosed 10–40 µg/day in 2–3 divided doses in symptomatic patients (MAXO: pharmacotherapy, NCIT:C15986; specific agent CHEBI desmopressin). - Hormone replacement for other pituitary axis deficiencies (levothyroxine for central hypothyroidism, hydrocortisone for ACTH deficiency, growth hormone for GH deficiency). - Anticonvulsant pharmacotherapy for seizures (agent selection individualized; no HPE-specific anticonvulsant regimen is established). - Antispasmodic/antispastic agents (oral baclofen/tizanidine-class agents) and intramuscular botulinum toxin injections for spasticity/dystonia management. - Pharmacologic acid-suppression/prokinetic therapy for gastroesophageal reflux.

Surgical/interventional: - Ventriculoperitoneal shunt placement for hydrocephalus (MAXO:0000004 surgical procedure). - Gastrostomy tube placement — used in the majority of alobar/semilobar HPE patients to secure safe nutrition, reduce aspiration risk, and reduce hospitalization burden; Nissen fundoplication or transpyloric feeding for severe reflux. - Craniofacial/plastic surgical repair of cleft lip/palate and other craniofacial anomalies. - Orthopedic surgery for refractory contractures, hip dislocation, or scoliosis.

Rehabilitative/supportive care: - Physical and occupational therapy (MAXO:0000011 physical therapy) to prevent/manage contractures and movement-disorder complications. - Speech-language therapy for feeding/swallowing dysfunction and communication support in higher-functioning individuals. - Detailed ophthalmologic and audiologic (hearing) evaluation and management. - Neuropsychological assessment and psychological/psychiatric intervention (ADHD, learning disability, anxiety, depression) in higher-functioning microform/lobar-spectrum individuals. - Genetic counseling (MAXO:0000079) is a core recommended component of care for the family, given the recurrence-risk complexity described in §9.

Experimental/advanced therapeutics: No SHH-HPE-specific gene therapy, cell therapy, or targeted molecular therapeutic is in active clinical development based on the sources reviewed; targeted searches of recent literature and ClinicalTrials.gov did not surface disease-modifying trials for HPE as of this writing — interventional trials registered under "holoprosencephaly" are predominantly natural-history/registry studies or trials of standard supportive interventions (e.g., anticonvulsants, feeding interventions) rather than SHH-pathway-targeted molecular therapies. This is consistent with the fundamental biological barrier that the causal lesion (failed embryonic midline patterning) occurs before pregnancy is typically recognized, making a postnatal molecular "fix" of the structural malformation implausible with current technology; therapeutic research in this space (to the extent any exists) would more plausibly target the SHH pathway pharmacologically in genetically at-risk pregnancies pre-conception or very early gestation, which is not an established or ethically straightforward intervention.

Treatment strategy: Management follows a complication-driven, multidisciplinary team model (genetics, neurology, neurosurgery, endocrinology, gastroenterology, ophthalmology, otolaryngology, plastic/craniofacial surgery, orthopedics, physiatry, psychology/psychiatry) rather than a fixed staged algorithm, individualized to HPE subtype and complication profile.

13. Prevention

Primary prevention: - Genetic counseling and family variant testing once a proband's causal SHH (or other HPE-gene) variant is identified — testing of apparently unaffected parents is essential given reduced penetrance, since "the family history of some individuals diagnosed with HPE may appear to be negative because of reduced penetrance and failure to recognize the disorder in family members" (GeneReviews). - Prenatal diagnosis (CVS/amniocentesis with targeted familial variant testing) once the familial pathogenic variant is known. - Preimplantation genetic testing (PGT) for known familial SHH variants has been clinically implemented (NEJM 2003). - Glycemic control in pregestational diabetic pregnancies — given the strong, modifiable association between poor glycemic control and HPE risk, optimized preconception and early-pregnancy glucose control is a plausible primary-prevention lever, though this is inferential from the epidemiologic association rather than an intervention specifically validated to reduce HPE incidence in the sources reviewed. - Avoidance of alcohol use in pregnancy, standard general teratogen-avoidance counseling (retinoic acid/vitamin A excess, known teratogenic medications). - Periconceptional folic acid supplementation — plausibly protective per limited epidemiologic data, though evidence strength is lower than for neural tube defects; reasonable to recommend as standard preconception care regardless.

Secondary prevention (early detection): - Routine anatomy-survey obstetric ultrasound (typically 18–22 weeks) is the principal population-level detection mechanism for structural (non-microform) HPE; earlier first-trimester detection is possible for severe forms. - Focused clinical craniofacial examination of "unaffected" parents/siblings of an HPE proband to detect subtle microform features (single central incisor, hypotelorism, hyposmia) that would otherwise be overlooked.

Genetic counseling — critical practice point: Counseling language should be carefully chosen; the literature explicitly recommends avoiding stigmatizing terms such as "not viable," "incompatible with life," or "vegetative," given the genuine phenotypic range (including surviving, communicative individuals with milder HPE subtypes) and should provide balanced, evidence-based prognostic information with referral to a genetic counselor or clinical geneticist.

Tertiary prevention: Standard complication-prevention measures embedded in the management plan above (aspiration-precaution feeding strategies/gastrostomy to prevent recurrent aspiration pneumonia, shunt surveillance to prevent hydrocephalus-related injury, endocrine surveillance to prevent undiagnosed adrenal crisis or severe hypothyroidism, orthopedic surveillance to prevent hip dislocation/severe scoliosis).

14. Other Species / Natural Disease

Taxonomy of naturally/experimentally affected species: Sheep (Ovis aries, NCBITaxon:9940), goats, and cattle (Bos taurus, NCBITaxon:9913) are documented to develop cyclopia/HPE-spectrum craniofacial-CNS malformations.

Natural/environmentally induced disease: - The classic natural-disease model is epidemic cyclopia/HPE among lambs on western U.S. sheep ranches, traced to maternal grazing on Veratrum californicum during a narrow gestational window (days 13–14 post-conception in sheep) — "Veratrum californicum fed to ewes on the 13th and 14th days after conception is capable of producing the anomaly" (54 Veratrum-Induced Placental Dysplasia in Sheep, USDA ARS). - The causative teratogens are steroidal jerveratrum alkaloids, principally cyclopamine, which directly inhibits Hedgehog pathway signal transduction (a direct SMO antagonist) — the historical discovery that established the mechanistic link between Hedgehog pathway inhibition and holoprosencephaly. - Sporadic veterinary case reports document naturally occurring holoprosencephaly/synophthalmia in domestic cattle — e.g., a Holstein-cross calf with "synophthalmia, holoprosencephaly, absence of optic chiasma, hypoplastic maxilla, curved mandibles, arrhinia and dental pad agenesis" (Synophthalmia in a Holstein cross calf, PMC4300002). - Comparative musculoskeletal analysis of cebocephalic and cyclopic lamb heads has been used to illuminate normal-vs-abnormal craniofacial developmental biology relevant to human pathology (Sci Rep 2018).

Orthologous gene/comparative biology: Shh is highly conserved across vertebrates (mouse, chick, zebrafish, sheep, human), and the ventral-forebrain-patterning function of the pathway is deeply evolutionarily conserved, underpinning the strong translational validity of animal Hedgehog-pathway models for human HPE (see §15).

Zoonotic potential: None — HPE is a non-transmissible developmental malformation, not an infectious disease; there is no zoonotic dimension.

15. Model Organisms

Mouse (Mus musculus, NCBITaxon:10090) — the primary genetic model: - Complete Shh-null (Shh−/−) mice display severe, essentially "worst-case" HPE-spectrum phenotypes, including cyclopia and single median telencephalic vesicle, phenocopying the most severe human alobar HPE/cyclopia end of the spectrum. - Heterozygous Shh+/− mice are, notably, largely phenotypically normal at baseline — directly modeling the incomplete penetrance seen in human heterozygous carriers — but develop overt HPE-spectrum phenotypes when combined with a second genetic hit (e.g., Gas1−/− background) or an environmental insult* (prenatal ethanol exposure), providing direct experimental proof of the multi-hit/threshold model of human HPE pathogenesis: "single allele mutations in the Hh pathway genes Sonic Hedgehog (SHH) and GLI2 cause holoprosencephaly with extremely variable phenotypic penetrance in humans," recapitulated by combinatorial mouse genetics. - Disp1-null and Smo-null mouse embryos exhibit a single telencephalic vesicle and cyclopia, confirming that loss of ligand release (Disp1) or ligand transduction (Smo) each independently phenocopies loss of the ligand itself. - Gli2-null and Gli2+/− mice**, alone and combined with ethanol exposure, model the GLI2-associated human HPE phenotype and the gene–environment interaction described in §2/§6 (PMC3929747). - Cdon-mutant mice combined with prenatal ethanol exposure produce HPE that can be rescued by reduced Ptch1 gene dosage — a genetic-rescue experiment directly demonstrating pathway-level dosage compensation as a therapeutic-relevant principle (PMC3823703). - Ectopic/gain-of-function Shh signaling experiments (elevated ventral signaling encroaching dorsally) impair telencephalic dorsal midline development via Fgf8 upregulation, illustrating that both loss and ectopic gain of pathway activity disrupt normal midline patterning — relevant to understanding the full mechanistic landscape even though loss-of-function is the dominant human-disease-causing direction (PMID:17468181).

Sheep (Ovis aries) — natural/pharmacologically-induced teratogenic model: described in §14; historically the model system that led to discovery of the Hedgehog pathway's role in mammalian ventral forebrain/facial patterning via cyclopamine.

Zebrafish (Danio rerio, NCBITaxon:7955): Zebrafish hedgehog-pathway mutants (e.g., loss of grk3) produce "stereotypical shh-deficient developmental phenotypes, such as cyclopia," useful for high-throughput developmental and small-molecule screening given rapid ex utero development and optical transparency. (Zebrafish ptch1-mutant models are more extensively used for SHH-pathway-driven medulloblastoma — a related but oncogenic, gain-of-function application of the same pathway — rather than developmental HPE modeling specifically.)

Model characteristics — recapitulation and limitations: - Mouse Shh/pathway-gene models recapitulate the core structural (cyclopia, single ventricle) and, in combinatorial/hypomorphic allelic series, the graded severity spectrum and incomplete penetrance of human HPE with high fidelity, making mouse genetics the dominant and most translationally informative model system for this disease. - A key limitation: full Shh-null mice model only the most extreme end of the human spectrum; capturing the clinically most common and counseling-relevant microform/reduced-penetrance end of the spectrum has required more sophisticated combinatorial (second-hit) or environmentally-sensitized allelic models rather than simple heterozygous mutants alone, since simple Shh+/− mice are typically phenotypically unremarkable. - Human forebrain organoid/iPSC-based models represent an emerging but, per the literature surveyed here, still comparatively less-developed complementary system for directly studying patient-derived SHH variant effects on human ventral telencephalic patterning in vitro.

Resources: MGI (Mouse Genome Informatics) for Shh, Gli2, Ptch1, Cdon, Gas1, Disp1, Smo allele/phenotype records; ZFIN for zebrafish hedgehog-pathway alleles; IMPC/KOMP for systematic knockout phenotyping resources.

Summary of Key Ontology Term Suggestions

Sources: - Holoprosencephaly Overview - GeneReviews - NCBI - NIH - Holoprosencephaly: Review of Embryology, Clinical Phenotypes, Etiology and Management, PMC10137117 - The unfolding clinical spectrum of holoprosencephaly due to mutations in SHH, ZIC2, SIX3 and TGIF genes, EJHG - Mutations in the human Sonic Hedgehog gene cause holoprosencephaly, Nature Genetics - Sonic hedgehog (SHH) mutation in patients within the spectrum of holoprosencephaly, ScienceDirect - Preimplantation Diagnosis for Sonic Hedgehog Mutation Causing Familial Holoprosencephaly, NEJM - Mutational Spectrum of the Sonic Hedgehog Gene in Holoprosencephaly, Human Molecular Genetics - Clinical utility gene card for: Holoprosencephaly, PMC3039493 - OMIM #236100 Holoprosencephaly 1 - OMIM #142945 Holoprosencephaly 3 - OMIM #610828 Holoprosencephaly 7 - Orphanet: Holoprosencephaly - Holoprosencephaly, Orphanet Journal of Rare Diseases - Epidemiological characteristics of holoprosencephaly in China, 2007-2014, PMC6553724 - Aberrant forebrain signaling during early development underlies HPE and coloboma, ScienceDirect - The Role of Sonic Hedgehog in Human Holoprosencephaly and Short-Rib Polydactyly Syndromes, PMC8468456 - Rescue of Holoprosencephaly in Fetal Alcohol-Exposed Cdon Mutant Mice, PMC3823703 - The Teratogenic Effects of Prenatal Ethanol Exposure Are Exacerbated by Sonic Hedgehog or Gli2 Haploinsufficiency, PMC3929747 - Frontiers: The Role of Sonic Hedgehog Pathway in CNS Development and Neurodegenerative Diseases - JCI: Pathogenesis of holoprosencephaly - Gas1 is a modifier for holoprosencephaly and genetically interacts with sonic hedgehog, PMID:17525797 - OMIM *139185 GAS1 - Endocrine disorders associated with holoprosencephaly, PMID:16355806 - Solitary median maxillary central incisor (SMMCI) syndrome, PMC1464380 - OMIM #147250 Solitary Median Maxillary Central Incisor - SHH curation results for Dosage Sensitivity, ClinGen - holoprosencephaly 5 MONDO:0012322, Monarch Initiative - 54 Veratrum-Induced Placental Dysplasia in Sheep, USDA ARS - Synophthalmia in a Holstein cross calf, PMC4300002 - Musculoskeletal study of cebocephalic and cyclopic lamb heads, Scientific Reports - Holoprosencephaly - Child Neurology Foundation

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: SHH Holoprosencephaly Spectrum
• MONDO ID: (if available)
• Category: Genetic

Research Objectives

Please provide a comprehensive research report on SHH Holoprosencephaly Spectrum covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: SHH Holoprosencephaly Spectrum (HPE3)

Target disease

• Disease name: SHH Holoprosencephaly Spectrum (SHH-related holoprosencephaly; HPE3)
• Category: Genetic congenital malformation / neurodevelopmental disorder
• MONDO ID: Not retrieved in the available evidence (not inferable from the current tool context).

1. Disease information

Overview (what is the disease?)

Holoprosencephaly (HPE) is a congenital forebrain malformation caused by inadequate or absent midline division of the prosencephalon/forebrain into cerebral hemispheres, frequently accompanied by midline craniofacial defects. SHH holoprosencephaly spectrum refers to the subset of HPE attributable to pathogenic variation affecting Sonic hedgehog (SHH) signaling and its dosage. (petryk2015holoprosencephalysignalinginteractions pages 1-3, lavillaureix2023aspectsgénétiquesdu pages 167-172)

Developmentally, HPE arises early in embryogenesis; one review places the critical window for failed cleavage at roughly gestational days 18–28. (lavillaureix2023aspectsgénétiquesdu pages 167-172)

Key identifiers and controlled vocabularies

• HPE locus name: HPE3, corresponding to the SHH gene (singh2009sonichedgehogmutations pages 1-2)
• Causal gene: SHH; location 7q36 (castro2021newshhand pages 1-2, singh2009sonichedgehogmutations pages 1-2)
• MeSH term (clinicaltrials.gov browse): Holoprosencephaly (MeSH D016142) (NCT04691414 chunk 1)

Synonyms / alternative names

• SHH-related holoprosencephaly
• Sonic hedgehog-related holoprosencephaly
• Holoprosencephaly 3 (HPE3)
• SHH-deficiency (SHH-D) spectrum / SHH-dosage disorders (used in some research contexts) (NCT04691414 chunk 1, lavillaureix2023aspectsgénétiquesdu pages 167-172)

Evidence source type

This entry is derived from aggregated disease-level resources (reviews) plus primary research (human genetics papers, mouse model studies) and clinicaltrials.gov registry descriptions (observational genetics studies). (petryk2015holoprosencephalysignalinginteractions pages 1-3, malta2023holoprosencephalyreviewof pages 9-11, kim2019integratedclinicaland pages 1-2, NCT04691414 chunk 1)

A compact scaffold of the key identifiers, definition, inheritance, and epidemiology is provided in the artifact table below.

Table: This table summarizes core disease-level facts for SHH-related holoprosencephaly spectrum, including naming, identifiers, overview, inheritance, and headline epidemiology. It is useful as a compact knowledge-base entry scaffold grounded only in the cited evidence contexts.

2. Etiology

Disease causal factors

Primary cause (genetic): Pathogenic variants affecting SHH and SHH-pathway genes reduce effective SHH signaling, producing a midline patterning defect of brain and face. SHH is repeatedly described as a major and historically first-identified gene in non-chromosomal HPE, with HPE3 mapping to SHH. (castro2021newshhand pages 1-2, singh2009sonichedgehogmutations pages 1-2, lavillaureix2023aspectsgénétiquesdu pages 167-172)

Mechanistic framing: Disruption of SHH signaling is described as a central pathophysiologic mechanism underlying HPE. (malta2023holoprosencephalyreviewof pages 9-11)

Risk factors

Genetic risk factors (driver and modifier genes): - Reviews emphasize that HPE commonly shows incomplete penetrance and variable expressivity, and that modifier effects/oligogenic inheritance contribute to phenotypic variability and diagnostic complexity. (petryk2015holoprosencephalysignalinginteractions pages 1-3, kim2019integratedclinicaland pages 1-2, lavillaureix2023aspectsgénétiquesdu pages 175-177) - In a large NGS study, Roessler et al. propose a “simple autosomal dominant with modifier pattern accounting for 25% of the molecular pathology” of HPE, while noting persistent unexplained incomplete penetrance/variable expressivity. (roessler2018commongeneticcauses pages 1-5) - In an integrative omics analysis under an oligogenic model, Kim et al. report variants of clinical interest across many genes enriched for pathways including SHH and primary cilia, and oligogenic events enriched in cases vs controls (P=10^-9). (kim2019integratedclinicaland pages 1-2)

Environmental/teratogenic risk factors (gene–environment interaction context): HPE has both genetic and environmental etiologies, and developmental biology reviews explicitly list examples such as maternal diabetes, ethanol, and retinoic acid as environmental causes/risks, with HPE often used as a model for multifactorial etiology. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Protective factors

Evidence for protective factors in the retrieved corpus is limited. One 2023 clinical review reports an association suggesting folic acid may be protective, citing a 73% risk reduction when taken in the first month in one study (details of the underlying study are not provided in the extracted text). (malta2023holoprosencephalyreviewof pages 9-11)

Gene–environment interactions

Direct experimental evidence that genetic lesions in the Hedgehog pathway can sensitize embryos to environmental teratogens is provided by mouse work in which heterozygous Gli2 variants increased penetrance/severity of HPE after low-dose exposure, supporting a mechanistic model where “normally silent genetic and environmental factors can interact to produce severe outcomes.” (petryk2015holoprosencephalysignalinginteractions pages 1-3)

3. Phenotypes

Conceptualization: “HPE spectrum” and SHH-specific variability

HPE is widely described as a nearly continuous spectrum, from severe malformations (e.g., alobar HPE with cyclopia) to mild microforms (e.g., solitary median maxillary central incisor, hypotelorism) that may occur with subtle or absent classic brain non-separation on imaging. (petryk2015holoprosencephalysignalinginteractions pages 1-3, lavillaureix2023aspectsgénétiquesdu pages 167-172, malta2023holoprosencephalyreviewof pages 2-4)

A key clinical point relevant for SHH-related disease is that facial severity often correlates with brain malformation severity, although exceptions exist by gene and mechanism. (lavillaureix2023aspectsgénétiquesdu pages 167-172, malta2023holoprosencephalyreviewof pages 2-4)

Radiologic/clinical subtypes (and a visual summary)

The 2023 clinical review provides a structured classification of HPE including alobar, semilobar, lobar, middle interhemispheric variant (MIH/syntelencephaly), and microforms/minimal forms. (malta2023holoprosencephalyreviewof pages 2-4)

The same review includes a classification table summarizing major radiologic and clinical features across the spectrum (Table 1 shown in the retrieved image). (malta2023holoprosencephalyreviewof media b1f62008)

Common clinical features and complications (selected)

From the 2023 review and a 2024 case review: - Hydrocephalus: reported frequency 16–40%; may require shunting. (malta2023holoprosencephalyreviewof pages 4-6) - Seizures/epilepsy: approximately ~50%. (malta2023holoprosencephalyreviewof pages 4-6) - Feeding/oromotor difficulties: common, including issues related to midline clefting. (malta2023holoprosencephalyreviewof pages 4-6) - Endocrine/hypothalamic–pituitary dysfunction: diabetes insipidus, adrenal hypoplasia, hypogonadism, thyroid hypoplasia, growth hormone deficiency are noted as common in some clinical summaries of HPE. (chafiq2024alobarholoprosencephalyin pages 1-3)

Suggested HPO terms (non-exhaustive; for knowledge base mapping)

The following HPO mappings are consistent with phenotypes described in the retrieved evidence: - Holoprosencephaly: HP:0001360 - Alobar holoprosencephaly: HP:0002506 - Semilobar holoprosencephaly: HP:0002510 - Lobar holoprosencephaly: HP:0002508 - Hypotelorism: HP:0000601 (petryk2015holoprosencephalysignalinginteractions pages 1-3, lavillaureix2023aspectsgénétiquesdu pages 167-172) - Cleft lip and/or palate: HP:0000204 / HP:0000175 (lavillaureix2023aspectsgénétiquesdu pages 167-172, malta2023holoprosencephalyreviewof pages 4-6) - Solitary median maxillary central incisor (SMMCI): HP:0006313 (petryk2015holoprosencephalysignalinginteractions pages 1-3, galeotti2024useofan pages 1-2) - Congenital nasal pyriform aperture stenosis (CNPAS): HP:0012722 (galeotti2024useofan pages 1-2) - Seizures: HP:0001250 (malta2023holoprosencephalyreviewof pages 4-6) - Hydrocephalus: HP:0000238 (malta2023holoprosencephalyreviewof pages 4-6)

Note: HPO IDs are provided for ontology mapping convenience; the underlying phenotype assertions are supported by the cited sources.

4. Genetic / molecular information

Causal gene

• SHH (Sonic Hedgehog) is the defining causal gene for HPE3/SHH-related holoprosencephaly spectrum. (castro2021newshhand pages 1-2, singh2009sonichedgehogmutations pages 1-2)

Pathogenic variant concepts

The retrieved evidence supports a range of mechanistic classes for reduced SHH signaling in HPE: - Haploinsufficiency / reduced effective dosage with incomplete penetrance and variable expressivity is emphasized in human families with heterozygous variants. (petryk2015holoprosencephalysignalinginteractions pages 1-3, castro2021newshhand pages 1-2) - Functional molecular work indicates SHH variants can disrupt distinct steps of SHH biogenesis to attenuate activity to different levels, and can also act in dominant-negative ways in some contexts (mechanistic summary in review-level extract). (singh2009sonichedgehogmutations pages 1-2)

Penetrance and expressivity (quantitative)

A developmental biology review reports that “Only about 37% of human carriers of SHH mutations develop HPE”, emphasizing incomplete penetrance. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Modifier genes / oligogenic inheritance

Multiple sources describe oligogenic inheritance and modifier effects: - An integrative clinical/omics approach found enrichment of variants across genes linked to forebrain development pathways including SHH and primary cilia, consistent with complex inheritance. (kim2019integratedclinicaland pages 1-2) - A 2023 genetics thesis-style review notes that many SHH-dosage cases remain genetically unsolved and highlights oligogenic inheritance and modifiers as contributors to variability. (lavillaureix2023aspectsgénétiquesdu pages 175-177)

Epigenetic information

No SHH-HPE-specific epigenetic (methylation/histone/chromatin) mechanisms were directly extracted in the retrieved evidence.

Chromosomal abnormalities

Although SHH-HPE is monogenic, HPE overall frequently includes chromosomal etiologies; recent case-based and review evidence notes that 25–50% of HPE may have chromosomal abnormalities (commonly trisomy 13). (galeotti2024useofan pages 1-2)

5. Environmental information

HPE etiology includes environmental/teratogenic contributors; reviews list maternal diabetes, ethanol, and retinoic acid among examples discussed in the context of multifactorial causation and gene–environment interactions. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

The retrieved evidence did not provide quantified attributable risk fractions for specific exposures in SHH-variant carriers.

6. Mechanism / pathophysiology

Key pathway (current understanding)

The canonical SHH pathway (ligand processing and downstream transduction via PTCH/SMO/GLI) is central to ventral midline patterning of the forebrain and craniofacial development; impaired activity is repeatedly described as causal for HPE phenotypes. (singh2009sonichedgehogmutations pages 1-2, malta2023holoprosencephalyreviewof pages 9-11)

Molecular causal chain (from trigger to phenotype)

1. Trigger: Germline pathogenic variation affecting SHH dosage/activity (or combined variants in SHH-pathway/modifier genes), sometimes combined with environmental exposures. (petryk2015holoprosencephalysignalinginteractions pages 1-3, kim2019integratedclinicaland pages 1-2)
2. Molecular consequence: Reduced effective SHH ligand activity. Mechanistically, SHH is produced as a preprotein that is cleaved into N- and C-terminal domains; the C-terminal domain mediates cholesterol modification of the N-terminal ligand, and the ligand is further palmitoylated, affecting secretion and signaling potency. (singh2009sonichedgehogmutations pages 1-2)
3. Signal transduction disruption: Altered activation of the Hedgehog signaling cascade involving PTCH/SMO and GLI transcription factors, reducing downstream transcriptional programs needed for ventral forebrain specification and midline craniofacial morphogenesis. (singh2009sonichedgehogmutations pages 1-2)
4. Developmental outcome: Failed or incomplete midline cleavage of the forebrain with a correlated craniofacial midline defect spectrum, yielding alobar/semilobar/lobar HPE and microforms. (malta2023holoprosencephalyreviewof pages 2-4, lavillaureix2023aspectsgénétiquesdu pages 167-172)

Upstream vs downstream

• Upstream: SHH ligand biogenesis (cleavage, lipid modification), secretion and dosage regulation; modifier genes that tune pathway strength; environmental factors that reduce pathway signaling below developmental thresholds. (singh2009sonichedgehogmutations pages 1-2, petryk2015holoprosencephalysignalinginteractions pages 1-3)
• Downstream: Reduced pathway-driven transcriptional patterning programs (GLI-dependent) leading to morphogenetic defects in brain and face. (singh2009sonichedgehogmutations pages 1-2, lavillaureix2023aspectsgénétiquesdu pages 167-172)

Gene–environment mechanism (example)

A mouse model demonstrates that Gli2 dosage-dependent attenuation of Hedgehog responsiveness can convert a “normally silent” predisposition into severe HPE outcomes when combined with a low-dose teratogen exposure, supporting a threshold model for pathway failure. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Suggested ontology terms

GO biological process (examples): - Hedgehog signaling pathway: GO:0007224 - Forebrain development: GO:0030900 - Craniofacial development: GO:0060322

Cell types (CL; examples likely involved): - Neuroepithelial cell / neural progenitor (ventral forebrain progenitors) - Cranial neural crest cell (relevant to craniofacial midline development)

Pathway resources: Mechanistic details align with canonical Hedgehog signaling represented in major pathway databases; however, pathway-database URLs were not retrieved in the current tool context.

7. Anatomical structures affected

Primary affected structures: - Forebrain/prosencephalon and midline brain structures (petryk2015holoprosencephalysignalinginteractions pages 1-3, malta2023holoprosencephalyreviewof pages 2-4) - Craniofacial midline (including nasal and oral structures) (lavillaureix2023aspectsgénétiquesdu pages 167-172, galeotti2024useofan pages 1-2)

Representative UBERON suggestions: - Forebrain: UBERON:0001890 - Prosencephalon: UBERON:0001891 - Face: UBERON:0001456 - Maxilla: UBERON:0002397

8. Temporal development

• Onset: Congenital; critical early embryonic window for prosencephalon cleavage is during early gestation (days ~18–28 in one summary). (lavillaureix2023aspectsgénétiquesdu pages 167-172)
• Progression/course: Structural malformation is non-progressive, but clinical course depends on severity and complications (hydrocephalus, seizures, endocrine dysfunction, feeding impairment), requiring long-term multidisciplinary care in survivors. (malta2023holoprosencephalyreviewof pages 4-6)

9. Inheritance and population

Epidemiology

HPE overall is commonly reported as occurring in approximately 1:250 conceptuses/fetuses and ~1:10,000 live births/live-born infants. (petryk2015holoprosencephalysignalinginteractions pages 1-3, roessler2018commongeneticcauses pages 1-5, lavillaureix2023aspectsgénétiquesdu pages 175-177)

Inheritance (SHH-related)

• Typically autosomal dominant with incomplete penetrance and variable expressivity. (petryk2015holoprosencephalysignalinginteractions pages 1-3, castro2021newshhand pages 1-2)
• Penetrance estimate reported in a review: ~37% of SHH mutation carriers develop HPE. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Genetic counseling implications

Because penetrance is incomplete and expressivity is variable, recurrence risk may be substantial when a pathogenic variant is present in a parent; one 2023 clinical review provides a general example of up to 50% recurrence risk when a parent carries a mutation with incomplete penetrance (not SHH-specific but relevant to autosomal-dominant HPE genes including SHH). (malta2023holoprosencephalyreviewof pages 9-11)

10. Diagnostics

Imaging

• Prenatal ultrasound: Severe forms can be detected in the first trimester; milder forms can be missed. (malta2023holoprosencephalyreviewof pages 9-11)
• Fetal MRI: recommended as a second-line prenatal study. (malta2023holoprosencephalyreviewof pages 9-11)
• Postnatal MRI: described as the imaging modality of choice for HPE diagnosis. (malta2023holoprosencephalyreviewof pages 9-11)

The 2024 case report/review also illustrates real-world practice: prenatal ultrasound diagnosis followed by postnatal brain MRI confirmation. (chafiq2024alobarholoprosencephalyin pages 1-3)

Genetic testing strategy (real-world implementation)

A 2023 clinical review proposes a stepwise approach: 1. Start with chromosomal analysis; if aneuploidy suspected use karyotype, otherwise chromosomal microarray (CMA) as first-line. (malta2023holoprosencephalyreviewof pages 9-11) 2. If unrevealing and/or syndromic, proceed to targeted gene panels or exome sequencing; the review reports ~22% yield for exome in a mixed cohort. (malta2023holoprosencephalyreviewof pages 9-11)

Clinical research implementations (NGS to improve counseling)

• NCT04691414 (EXOMEDIANE; Rennes University Hospital): retrospective NGS on biobanked DNA to improve genetic counseling for craniofacial midline defects/HPE, noting that “70% of cases … do not have a molecular diagnosis” in their summary rationale. Posted 2020-12-31; completed 2021-12-06. URL: https://clinicaltrials.gov/study/NCT04691414 (NCT04691414 chunk 1)
• NCT00645645 (NIH NHGRI): long-running observational cohort emphasizing mutational analysis of HPE genes; the registry summary states: “Mutations in one such gene, Sonic Hedgehog, have been shown by us to be responsible for approximately one quarter of familial cases of HPE.” First posted 2008-03-28; updated 2021-12-14. URL: https://clinicaltrials.gov/study/NCT00645645 (NCT00645645 chunk 1)

Differential diagnosis

The retrieved evidence emphasizes that HPE has heterogeneous etiologies including chromosomal anomalies and other monogenic syndromes; a structured differential diagnosis list was not directly extracted in the available snippets. (malta2023holoprosencephalyreviewof pages 9-11, galeotti2024useofan pages 1-2)

11. Outcome / prognosis

Survival and mortality (statistics)

A 2024 case review and the 2023 clinical review provide quantitative survival statistics for severe HPE (particularly alobar): - ~33% die within the first 24 hours - ~58% die within the first month - ~29% survive to 1 year (chafiq2024alobarholoprosencephalyin pages 4-5, malta2023holoprosencephalyreviewof pages 4-6)

Morbidity

Survivors frequently require long-term multidisciplinary care due to neurologic disability, seizures, feeding difficulties, endocrine dysfunction, and complications such as hydrocephalus. (chafiq2024alobarholoprosencephalyin pages 1-3, malta2023holoprosencephalyreviewof pages 4-6)

12. Treatment

Disease-modifying therapy

No disease-modifying pharmacotherapy for congenital SHH-related HPE was identified in the retrieved evidence. Management is described as supportive and multidisciplinary. (petryk2015holoprosencephalysignalinginteractions pages 1-3, malta2023holoprosencephalyreviewof pages 4-6)

Supportive and interventional care (real-world implementations)

• Hydrocephalus management: shunt placement when needed (hydrocephalus frequency 16–40%). (malta2023holoprosencephalyreviewof pages 4-6)
• Seizure management: antiepileptic treatment guided by clinical neurology (seizures ~50%). (malta2023holoprosencephalyreviewof pages 4-6)
• Feeding support: addressing feeding difficulties, sometimes related to clefts. (malta2023holoprosencephalyreviewof pages 4-6)
• Endocrine management: addressing diabetes insipidus and pituitary hormone deficiencies in affected individuals. (chafiq2024alobarholoprosencephalyin pages 1-3)

Example of implemented craniofacial/airway management in mild-spectrum HPE: - In an infant with mild HPE features (SMMCI) and congenital nasal pyriform aperture stenosis (CNPAS), a combined ENT–orthodontic approach used balloon dilation and a neonatal palatal expander plate to improve airway patency and sucking/swallowing. (May 2024; https://doi.org/10.3390/children11050554) (galeotti2024useofan pages 1-2)

Suggested MAXO terms (examples)

• Genetic counseling: MAXO:0000077 (term label may vary across MAXO versions)
• Magnetic resonance imaging: MAXO:0000715 (imaging procedure term; label may vary)
• Ventriculoperitoneal shunt placement / CSF shunting: surgical intervention term
• Feeding support / enteral feeding: supportive care term

(MAXO IDs are suggested for mapping; specific MAXO identifiers should be validated against the version used in your KB.)

13. Prevention

Primary prevention

No specific primary prevention is established for SHH-variant carriers in the retrieved evidence. One review states “Currently, there are no effective preventive methods for HPE,” emphasizing the need for deeper mechanistic understanding for prevention. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Secondary prevention / early detection

• Prenatal screening/diagnosis via ultrasound and fetal MRI facilitates counseling and perinatal planning. (malta2023holoprosencephalyreviewof pages 9-11, chafiq2024alobarholoprosencephalyin pages 1-3)

Counseling and reproductive options

The 2023 clinical review emphasizes balanced prognostic counseling and involving genetics professionals for recurrence estimation; prenatal genetic testing via amniotic fluid is possible. (malta2023holoprosencephalyreviewof pages 9-11)

14. Other species / natural disease

The retrieved evidence did not provide naturally occurring veterinary cases for SHH-related HPE. However, experimental developmental biology literature highlights conserved SHH function across vertebrates, and the phenotype is commonly modeled in mice. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

15. Model organisms

Key models and what they show

• Shh-null mouse embryos: described as having fully penetrant severe HPE, supporting a strong causal role for SHH in midline development and providing a baseline for understanding incomplete penetrance in humans. (petryk2015holoprosencephalysignalinginteractions pages 1-3)
• Gli2 gene–environment interaction mouse model: heterozygous Gli2 variants increase penetrance/severity after low-dose teratogen exposure, demonstrating a mechanistic basis for variable expressivity and prevention-focused research framing. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Model limitations

Mouse Shh-null is fully penetrant and typically much more severe than the human heterozygous state, limiting direct translation to human incomplete penetrance scenarios but enabling mechanistic dissection of pathway thresholds and modifier effects. (petryk2015holoprosencephalysignalinginteractions pages 1-3)

Recent developments and latest research emphasis (2023–2024)

1. Updated, clinically oriented synthesis (2023): Malta et al. (Mar 2023; https://doi.org/10.3390/children10040647) consolidates classification, imaging-based diagnosis, genetic testing strategy (CMA→panel/exome), complication rates (e.g., hydrocephalus 16–40%, seizures ~50%), and survival statistics, reflecting current clinical workflows. (malta2023holoprosencephalyreviewof pages 4-6, malta2023holoprosencephalyreviewof pages 9-11)
2. Implementation-level multidisciplinary care reports (2024): case reports describe integrated surgical/orthodontic airway management for CNPAS in mild-spectrum HPE, demonstrating real-world interventions for survivable sub-phenotypes. (May 2024; https://doi.org/10.3390/children11050554) (galeotti2024useofan pages 1-2)
3. Improving diagnostic yield and counseling via NGS (ongoing/registry evidence): EXOMEDIANE (NCT04691414) and NIH cohort protocols (NCT00645645) indicate continuing efforts to use sequencing to improve gene discovery and counseling, reflecting the recognized gap that many cases remain molecularly unsolved. (NCT04691414 chunk 1, NCT00645645 chunk 1)

Expert opinion / analysis (from authoritative sources in the retrieved evidence)

• Incomplete penetrance and variable expressivity are fundamental to SHH-related HPE and remain partially unexplained despite large-scale sequencing, supporting continued work on modifier genes and gene–environment interactions. (roessler2018commongeneticcauses pages 1-5, petryk2015holoprosencephalysignalinginteractions pages 1-3)
• The current best-supported clinical approach prioritizes imaging for diagnosis/severity stratification and uses a tiered genetic testing strategy (chromosomal analysis → sequencing), aligning with the heterogeneity of causes. (malta2023holoprosencephalyreviewof pages 9-11)

Notes on gaps / limitations of this report

• Formal mapping to MONDO, Orphanet, ICD-10/ICD-11 identifiers and SHH OMIM IDs was not retrievable from the current tool evidence; these should be added from OMIM/Orphanet in a subsequent pass.
• Variant-level details (HGVS, ClinVar frequencies, gnomAD allele frequencies) were not directly accessible in the retrieved text snippets; therefore, variant cataloging is limited to conceptual classes rather than enumerated variants.

Key citations (URLs and dates where available)

• Malta M, et al. Children. 2023-03. “Holoprosencephaly: Review of Embryology, Clinical Phenotypes, Etiology and Management.” https://doi.org/10.3390/children10040647 (malta2023holoprosencephalyreviewof pages 4-6, malta2023holoprosencephalyreviewof pages 9-11)
• Chafiq K, et al. Cureus. 2024-11. “Alobar Holoprosencephaly in a Newborn: A Case Report…” https://doi.org/10.7759/cureus.74462 (chafiq2024alobarholoprosencephalyin pages 4-5, chafiq2024alobarholoprosencephalyin pages 1-3)
• Petryk A, et al. WIREs Dev Biol. 2015-10. https://doi.org/10.1002/wdev.161 (petryk2015holoprosencephalysignalinginteractions pages 1-3)
• Roessler E, et al. Hum Mutat. 2018-07. https://doi.org/10.1002/humu.23590 (roessler2018commongeneticcauses pages 1-5)
• Kim A, et al. Brain. 2019-11. https://doi.org/10.1093/brain/awy290 (kim2019integratedclinicaland pages 1-2)
• de Castro VF, et al. Molecular Syndromology. 2021-06. https://doi.org/10.1159/000515044 (castro2021newshhand pages 1-2)
• Singh S, et al. Hum Genet. 2009-12. https://doi.org/10.1007/s00439-008-0599-0 (singh2009sonichedgehogmutations pages 1-2)
• ClinicalTrials.gov NCT04691414 (EXOMEDIANE). First posted 2020-12-31; completed 2021-12-06. https://clinicaltrials.gov/study/NCT04691414 (NCT04691414 chunk 1)
• ClinicalTrials.gov NCT00645645. First posted 2008-03-28; updated 2021-12-14. https://clinicaltrials.gov/study/NCT00645645 (NCT00645645 chunk 1)

References

1. (petryk2015holoprosencephalysignalinginteractions pages 1-3): Anna Petryk, Daniel Graf, and Ralph Marcucio. Holoprosencephaly: signaling interactions between the brain and the face, the environment and the genes, and the phenotypic variability in animal models and humans. Wiley Interdisciplinary Reviews: Developmental Biology, 4:17-32, Oct 2015. URL: https://doi.org/10.1002/wdev.161, doi:10.1002/wdev.161. This article has 132 citations.

2. (lavillaureix2023aspectsgénétiquesdu pages 167-172): A Lavillaureix. Aspects génétiques du développement cérébral, holoprosencéphalie et élargissement du spectre phénotypique aux pathologies liées à la voie de signalisation shh. Unknown journal, 2023.

3. (singh2009sonichedgehogmutations pages 1-2): Samer Singh, Robert Tokhunts, Valerie Baubet, John A. Goetz, Zhen Jane Huang, Neal S. Schilling, Kendall E. Black, Todd A. MacKenzie, Nadia Dahmane, and David J. Robbins. Sonic hedgehog mutations identified in holoprosencephaly patients can act in a dominant negative manner. Human Genetics, 125:95-103, Dec 2009. URL: https://doi.org/10.1007/s00439-008-0599-0, doi:10.1007/s00439-008-0599-0. This article has 44 citations and is from a peer-reviewed journal.

4. (castro2021newshhand pages 1-2): Viviane Freitas de Castro, Daniel Mattos, Flavia Martinez de Carvalho, Denise Pontes Cavalcanti, Milagros M. Duenas-Roque, Juan Llerena Jr, Viviana Raquel Cosentino, Rachel Sayuri Honjo, Julio Cesar Loguercio Leite, Maria Teresa Sanseverino, Márcia Pereira Alves de Souza, Pricila Bernardi, Ana Maria Bolognese, Luiz Carlos Santana da Silva, Pablo Barbero, Patricia Santana Correia, Larissa Souza Mario Bueno, Clarice Pagani Savastano, and Iêda Maria Orioli. New shh and known six3 variants in a series of latin american patients with holoprosencephaly. Molecular Syndromology, 12:219-233, Jun 2021. URL: https://doi.org/10.1159/000515044, doi:10.1159/000515044. This article has 3 citations and is from a peer-reviewed journal.

5. (NCT04691414 chunk 1): Retrospective Study Using Next Generation Sequencing (NGS) on Biological Samples to Improve Genetic Counseling for Patients With Previously Explored Craniofacial Midline Defects.. Rennes University Hospital. 2021. ClinicalTrials.gov Identifier: NCT04691414

6. (malta2023holoprosencephalyreviewof pages 9-11): Maísa Malta, Rowim AlMutiri, Christine Saint Martin, and Myriam Srour. Holoprosencephaly: review of embryology, clinical phenotypes, etiology and management. Children, 10:647, Mar 2023. URL: https://doi.org/10.3390/children10040647, doi:10.3390/children10040647. This article has 37 citations.

7. (kim2019integratedclinicaland pages 1-2): Artem Kim, Clara Savary, Christèle Dubourg, Wilfrid Carré, Charlotte Mouden, Houda Hamdi-Rozé, Hélène Guyodo, Jerome Le Douce, Emmanuelle Génin, Dominique Campion, Jean-François Dartigues, Jean-François Deleuze, Jean-Charles Lambert, Richard Redon, Thomas Ludwig, Benjamin Grenier-Boley, Sébastien Letort, Pierre Lindenbaum, Vincent Meyer, Olivier Quenez, Christian Dina, Céline Bellenguez, Camille Charbonnier-Le Clézio, Joanna Giemza, Stéphanie Chatel, Claude Férec, Hervé Le Marec, Luc Letenneur, Gaël Nicolas, Karen Rouault, Delphine Bacq, Anne Boland, Doris Lechner, Cisca Wijmenga, Morris A Swertz, P Eline Slagboom, Gert-Jan B van Ommen, Cornelia M van Duijn, Dorret I Boomsma, Paul I W de Bakker, Jasper A Bovenberg, P Eline Slagboom, Anton J M de Craen, Marian Beekman, Albert Hofman, Dorret I Boomsma, Gonneke Willemsen, Bruce Wolffenbuttel, Mathieu Platteel, Yuanping Du, Ruoyan Chen, Hongzhi Cao, Rui Cao, Yushen Sun, Jeremy Sujie Cao, Morris A Swertz, Freerk van Dijk, Pieter B T Neerincx, Patrick Deelen, Martijn Dijkstra, George Byelas, Alexandros Kanterakis, Jan Bot, Kai Ye, Eric-Wubbo Lameijer, Martijn Vermaat, Jeroen F J Laros, Johan T den Dunnen, Peter de Knijff, Lennart C Karssen, Elisa M van Leeuwen, Najaf Amin, Vyacheslav Koval, Fernando Rivadeneira, Karol Estrada, Jayne Y Hehir-Kwa, Joep de Ligt, Abdel Abdellaoui, Jouke-Jan Hottenga, V Mathijs Kattenberg, David van Enckevort, Hailiang Mei, Mark Santcroos, Barbera D C van Schaik, Robert E Handsaker, Steven A McCarroll, Evan E Eichler, Arthur Ko, Peter Sudmant, Laurent C Francioli, Wigard P Kloosterman, Isaac J Nijman, Victor Guryev, Paul I W de Bakker, Laurent Pasquier, Elisabeth Flori, Marie Gonzales, Claire Bénéteau, Odile Boute, Tania Attié-Bitach, Joelle Roume, Louise Goujon, Linda Akloul, Sylvie Odent, Erwan Watrin, Valérie Dupé, Marie de Tayrac, and Véronique David. Integrated clinical and omics approach to rare diseases: novel genes and oligogenic inheritance in holoprosencephaly. Brain, 142:35-49, Nov 2019. URL: https://doi.org/10.1093/brain/awy290, doi:10.1093/brain/awy290. This article has 60 citations and is from a highest quality peer-reviewed journal.

8. (chafiq2024alobarholoprosencephalyin pages 1-3): Kamal Chafiq, Khalil Toumi, Fatima Ezzahra Khayi, and Abdellatif Daoudi. Alobar holoprosencephaly in a newborn: a case report of prenatal diagnosis and a review of the literature. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.74462, doi:10.7759/cureus.74462. This article has 4 citations.

9. (roessler2018commongeneticcauses pages 1-5): E. Roessler, P. Hu, Juliana Marino, Sungkook Hong, R. Hart, Seth I. Berger, Ariel F. Martinez, Yu Abe, P. Kruszka, James W. Thomas, J. Mullikin, Nisc Comparative Sequencing Program, Yupeng Wang, Wendy S. W. Wong, J. Niederhuber, Benjamin D. Solomon, Benjamin D. Solomon, A. Richieri‐Costa, L. Ribeiro-Bicudo, and M. Muenke. Common genetic causes of holoprosencephaly are limited to a small set of evolutionarily conserved driver genes of midline development coordinated by tgf‐β, hedgehog, and fgf signaling. Human Mutation, 39:1416-1427, Jul 2018. URL: https://doi.org/10.1002/humu.23590, doi:10.1002/humu.23590. This article has 31 citations and is from a domain leading peer-reviewed journal.

10. (lavillaureix2023aspectsgénétiquesdu pages 175-177): A Lavillaureix. Aspects génétiques du développement cérébral, holoprosencéphalie et élargissement du spectre phénotypique aux pathologies liées à la voie de signalisation shh. Unknown journal, 2023.

11. (malta2023holoprosencephalyreviewof pages 2-4): Maísa Malta, Rowim AlMutiri, Christine Saint Martin, and Myriam Srour. Holoprosencephaly: review of embryology, clinical phenotypes, etiology and management. Children, 10:647, Mar 2023. URL: https://doi.org/10.3390/children10040647, doi:10.3390/children10040647. This article has 37 citations.

12. (malta2023holoprosencephalyreviewof media b1f62008): Maísa Malta, Rowim AlMutiri, Christine Saint Martin, and Myriam Srour. Holoprosencephaly: review of embryology, clinical phenotypes, etiology and management. Children, 10:647, Mar 2023. URL: https://doi.org/10.3390/children10040647, doi:10.3390/children10040647. This article has 37 citations.

13. (malta2023holoprosencephalyreviewof pages 4-6): Maísa Malta, Rowim AlMutiri, Christine Saint Martin, and Myriam Srour. Holoprosencephaly: review of embryology, clinical phenotypes, etiology and management. Children, 10:647, Mar 2023. URL: https://doi.org/10.3390/children10040647, doi:10.3390/children10040647. This article has 37 citations.

14. (galeotti2024useofan pages 1-2): Angela Galeotti, Giovanni Carlo De Vincentiis, Emanuela Sitzia, Giuseppe Marzo, Wanda Maldonato, Gaia Bompiani, Maria Beatrice Chiarini Testa, Alessandra Putrino, Andrea Bartuli, and Paola Festa. Use of an orthodontic and otolaryngological approach in an infant with holoprosencephaly. Children, 11:554, May 2024. URL: https://doi.org/10.3390/children11050554, doi:10.3390/children11050554. This article has 6 citations.

15. (NCT00645645 chunk 1): A Study of the Genetic Analysis of Brain Disorders. National Human Genome Research Institute (NHGRI). 2008. ClinicalTrials.gov Identifier: NCT00645645

16. (chafiq2024alobarholoprosencephalyin pages 4-5): Kamal Chafiq, Khalil Toumi, Fatima Ezzahra Khayi, and Abdellatif Daoudi. Alobar holoprosencephaly in a newborn: a case report of prenatal diagnosis and a review of the literature. Cureus, Nov 2024. URL: https://doi.org/10.7759/cureus.74462, doi:10.7759/cureus.74462. This article has 4 citations.

SHH Holoprosencephaly Spectrum — Comprehensive Disease Characterization Report

Disease: SHH Holoprosencephaly Spectrum (HPE3) Category: Genetic (autosomal dominant, developmental) Key identifiers: OMIM #142945 (HPE3); SHH gene OMIM *600725; MONDO:0016296; ORPHA:2162; ICD-10 Q04.2; ICD-11 LA05.0; MeSH D016142; HGNC:10848 (SHH); UniProt Q15465; Ensembl ENSG00000164690

Evidence source labels: [H] human clinical/registry, [M] model organism, [V] in vitro, [C] computational/structural. PMIDs cited inline.

Summary

SHH holoprosencephaly (HPE3) is the most common single-gene, non-chromosomal cause of holoprosencephaly (HPE) — the failure of the embryonic forebrain (prosencephalon) to cleave into two cerebral hemispheres between the 18th and 28th day of gestation. It is an autosomal-dominant disorder caused by heterozygous loss-of-function of Sonic Hedgehog (SHH), which lowers SHH morphogen signaling in the rostroventral forebrain during a narrow developmental window. The consequence is a graded midline brain–face malformation continuum, spanning cyclopia and alobar HPE at the severe end through semilobar, lobar, and the middle interhemispheric variant, down to isolated "microforms" (solitary median maxillary central incisor [SMMCI], ocular hypotelorism) at the mild end. SHH is the first-identified and most frequently mutated of at least seven implicated HPE genes (SHH, ZIC2, SIX3, TGIF, PTCH1, GLI2, TDGF1) and underlies ~17% of familial HPE.

A defining feature is extreme variability: markedly incomplete penetrance and highly variable expressivity mean a single variant can produce lethal brain malformation in one relative and only a subtle facial sign — or nothing detectable — in another. Critically, in the largest genotype–phenotype cohort (396 individuals), SHH variants biased toward the milder end, more often causing non-HPE (64%) than frank HPE (36%), and mutation-positive microform carriers may have normal or even above-average intellect. This variability reflects a "multiple-hit" genetic architecture (co-occurring variants in modifiers such as GAS1, and pathways including NODAL, NOTCH, WNT/PCP, FGF, RAS/ERK, cilia, and cohesin) combined with gene–environment interaction, most prominently maternal pregestational diabetes, with additional signals from alcohol, female sex, and twinning.

Clinically, HPE carries among the lowest survival of all rare structural congenital anomalies (~36% at 10 years; alobar HPE is usually lethal neonatally). No curative or disease-modifying therapy exists; care is supportive and centers on prenatal imaging diagnosis, genetic counseling with molecular cascade testing, and management of the characteristic complications — seizures, autonomic instability, and hypothalamic–pituitary endocrinopathy, of which central diabetes insipidus (~47% of HPE patients) is the hallmark. Causation is definitively established by the landmark Shh-null mouse (cyclopia, loss of the ventral neural tube), and human SHH variants have been functionally validated in zebrafish rescue assays.

Key Findings

Finding 1 — SHH is the leading single-gene cause of HPE, acting via haploinsufficiency of Sonic Hedgehog signaling

Holoprosencephaly results from incomplete cleavage of the prosencephalon between the 18th and 28th days of gestation. At least seven genes are positively implicated, of which SHH was the first identified and is the most frequently mutated (PMID: 17274816: "To date, seven genes have been positively implicated in HPE: Sonic hedgehog (SHH), ZIC2, SIX3, TGIF, PTCH, GLI2 and TDGF1."). The convergent mechanism across these diverse genes is disruption of Hedgehog signaling — "disruption of Sonic hedgehog expression and/or signaling in the rostroventral region of the embryo is a major common effect of these mutations" (PMID: 19186244). Inheritance is autosomal dominant with markedly incomplete penetrance and variable expressivity: "even HPE in pedigrees is characterized by incomplete penetrance and variable expressivity" (PMID: 19186244). The molecular basis is haploinsufficiency — loss of one functional SHH allele lowers morphogen output below the threshold required for normal midline forebrain patterning. [H/M]

Finding 2 — HPE forms a graded clinical spectrum with correlated brain–face severity

HPE is classically divided into three ranges of increasing severity — lobar, semilobar, and alobar — plus the milder middle interhemispheric variant (MIHV/syntelencephaly) (PMID: 17274816: "Three ranges of increasing severity are described: lobar, semi-lobar and alobar HPE."). Facial anomalies parallel brain severity along the "face predicts the brain" principle: severe forms show "cyclopia, proboscis, median or bilateral cleft lip/palate," while minor forms show "ocular hypotelorism or solitary median maxillary central incisor", and microforms can occur with a structurally normal brain (PMID: 17274816). A nationwide Japanese survey (n=49 anatomically typed) found: 40.8% alobar, 40.8% semilobar, 10.4% lobar (PMID: 31886593: "20 were alobar (40.8%), 20 were semilobar (40.8%), five were lobar (10.4%)"). [H]

Finding 3 — HPE has the lowest survival among rare structural congenital anomalies

Birth prevalence is ~1/16,000 live births but ~1/250 conceptuses, indicating that the great majority of affected pregnancies are lost in utero (PMID: 17274816: "It is estimated to occur in 1/16,000 live births and 1/250 conceptuses."); Japan's birth-prevalence rate was 1.54/10,000 live births (PMID: 31886593). Two independent registries confirm HPE has the worst survival of the conditions studied:

"Arhinencephaly/holoprosencephaly had the lowest survival at all ages" (PMID: 35351164); "Ten-year survival varied by condition, ranging from 36.9% for holoprosencephaly to 99.3% for pyloric stenosis" (PMID: 37868647). Prognosis is strongly severity-dependent; alobar HPE is uniformly unfavorable neonatally. [H]

Finding 4 — Penetrance/expressivity are shaped by "multiple-hit" genetics and gene–environment interaction

Clinical expression is "extremely variable" and is attributed to the number and type of HPE gene variants, with environmental agents contributing and evidence for a "multiple hits" requirement — e.g., patients carrying combined GAS1 + SHH variants (PMID: 20583177: "Environmental agents may also contribute to the severity as well as the requirement of multiple hits."). Recent reviews implicate modifiers across the NODAL, NOTCH, WNT/PCP, FGF, and RAS/ERK1/2 pathways plus ciliary and cohesin components (PMID: 41102431: "These include modulators of the NODAL, NOTCH, WNT/PCP, FGF, and RAS/ERK1/2 pathways as well as components of ciliary structures and cohesin complexes."), and emphasize that "incomplete penetrance, broad phenotypic heterogeneity, and gene-environment interactions complicate diagnostic and counselling efforts" (PMID: 41102431). Mechanistically, SHH signaling requires cholesterol modification of the ligand and a coreceptor handoff via GAS1/SCUBE2 to PTCH1 (PMID: 35231446: "how GAS1 recognizes the SHH palmitate and cholesterol modifications in modular fashion and how it facilitates lipid-dependent SHH handoff to PTCH1"), providing a molecular bridge between sterol-disrupting exposures and HPE risk. [H/V/C]

Finding 5 — SHH accounts for ~17% of familial HPE; ligand lipidation is required; human variants are functionally validated

"Mutations in SHH underlie most familial (17%) cases of HPE" (PMID: 23055936). The same study established that Hedgehog acyltransferase (Hhat), required for N-terminal palmitoylation of SHH, is essential: "Hhat is required for post-translational palmitoylation of Hedgehog (Hh) proteins; and, in the absence of Hhat, Hh secretion from producing cells is diminished" (PMID: 23055936). Loss of Hhat in mouse produces severe acrania-holoprosencephaly-agnathia by diminishing SHH secretion and perturbing long-range signaling, with downstream disruption of FGF, BMP, and ERK and extensive apoptosis in craniofacial primordia. Because "only a minor fraction of known SHH variants have been experimentally proven to lead to abnormal function" (PMID: 32939873), human missense variants have been functionally validated by phenotypic rescue in a shha CRISPR/Cas9 zebrafish assay — an important tool given the abundance of variants of uncertain significance (VUS). [M/V]

Finding 6 — Hypothalamic–pituitary dysfunction (central diabetes insipidus ~47%) and extracephalic involvement are key managed features

Endocrine dysfunction is a central management issue. In a cohort screened for SHH/GLI2, "Diabetes insipidus was common in patients with HPE (47%) but infrequent in patients with congenital hypopituitarism or SOD (7% and 8%, respectively)" (PMID: 25056824); anterior pituitary deficiency occurred in 53% of HPE patients, and a heterozygous nonsense SHH variant (p.Tyr175Ter) was found in an alobar HPE patient with hypopituitarism. In human (typically heterozygous) HPE, "the pituitary gland, no matter how hypoplastic, is present in most cases of human holoprosencephaly, unlike animals in which it is always said to be absent" (PMID: 20013843) — a dosage difference between heterozygous human and homozygous animal models. Beyond brain and face, nonchromosomal nonsyndromic HPE shows "a wide spectrum of extracephalic manifestations" across organ systems (PMID: 29761634). [H]

Finding 7 — Mutation-positive microform HPE can present with normal or above-average intellect

A finding that reframes genetic counseling: Solomon et al. presented 5 patients with clear microform HPE signs, all with above-average intellect, molecular cause identified in 4/5 (SHH, SIX3, GLI2, FGF8) (PMID: 23112757: "Here we present 5 patients with clear phenotypic signs of microform holoprosencephaly, all of whom have evidence of above-average intellectual function."). This contradicts the assumption that intellectual disability marks the mildly affected carrier parent and captures the full expressivity range "ranging from brain malformations incompatible with life to individuals with normal brain findings and subtle midline facial differences" (PMID: 23112757). Cognitive status therefore cannot be used to identify carriers — molecular testing of at-risk relatives is required. [H]

Finding 8 — SHH variants skew toward the mild end; truncating variants are more severe than non-truncating

In the largest SHH cohort (396 individuals, 157 kindreds), "SHH mutations more commonly resulted in non-HPE (64%) than frank HPE (36%), and non-HPE was significantly more common in patients with SHH than in those with mutations in the other common HPE related genes (p<0.0001 compared to ZIC2 or SIX3)" (PMID: 22791840). Within SHH, a genotype–severity gradient exists: "Individuals with truncating mutations were significantly more likely to have frank HPE than those with non-truncating mutations (49% vs 35%, respectively; p=0.012)" (PMID: 22791840), with N-terminal clustering. A European series of 645 probands (4-gene yield 25%) confirmed positional biology: "the most severe HPE types were associated with SIX3 and ZIC2 mutations, whereas microforms were associated with SHH mutations" (PMID: 21940735); a brain–face correlation held for SHH/SIX3/TGIF but not ZIC2. Inheritance differs by gene: "The SHH, SIX3, and TGIF mutations were inherited in more than 70% of these cases, whereas 70% of the mutations in ZIC2 occurred de novo" (PMID: 21940735).

[H]

Finding 9 — Nongenetic risk factors: maternal pregestational diabetes, female predominance, twinning, alcohol

A systematic review identified "maternal diabetes, twinning, and a predominance of females" as consistently replicated nongenetic risk factors (PMID: 29761639). A case-control study found maternal pregestational diabetes in 9.2% of cases vs 0% of controls (p=.02), plus elevated odds for alcohol (aOR 1.73) and aerosol/hair-spray exposure (aOR 2.46), and significant gene–environment interactions (PMID: 33111505: "maternal pregestational diabetes (9.2% of cases and 0 controls, p = .02)"). A meta-analysis of >80 million births ranked HPE among the highest anomaly-specific risks with pregestational diabetes (RR ~18.18, 95% CI 4.03–82.06) (PMID: 35104296); the National Birth Defects Prevention Study reported aOR 13.1 (95% CI 7.0–24.5) (PMID: 31454511). In an adult HPE cohort, "Factors associated with long-term survival included HPE subtype not alobar, female gender, and nontypical facial features" (PMID: 28640243). [H]

Finding 10 — Definitive genetic proof from mouse; specific alleles produce isolated microforms

The landmark targeted Shh knockout established causation: Shh "plays a critical role in patterning of vertebrate embryonic tissues," with early defects "in the establishment or maintenance of midline structures, such as the notochord and the floorplate" and later defects including "absence of distal limb structures, cyclopia, absence of ventral cell types within the neural tube" (PMID: 8837770) — directly recapitulating human HPE. At the mild extreme, the SHH missense allele I111F segregated with solitary median maxillary central incisor (SMMCI) without HPE, and "this mutation may be specific for the SMMCI phenotype since it has not been found in the HPE population or in normal controls" (PMID: 11471164). SMMCI can associate with pituitary insufficiency, short stature, microcephaly, and congenital nasal pyriform aperture stenosis. [M/H]

Mechanistic Model / Interpretation

SHH-HPE is best understood as a threshold disorder of morphogen dosage. SHH is a graded morphogen that patterns the ventral midline of the developing forebrain via the prechordal plate. A single loss-of-function allele lowers total signaling; whether the phenotype crosses into frank HPE, a microform, or clinical normality depends on whether SHH output at gestational days 18–28 falls above or below the patterning threshold. That threshold is not fixed — it is modulated by variant severity, genetic background/additional hits, and environmental inputs.

GENETIC              +           ENVIRONMENT
  (SHH LOF + modifiers)              (diabetes, alcohol, sterol disruption)
     \                              /
      \                            /
       ▼                          ▼
      ── Net SHH signaling at GD 18–28 (rostroventral forebrain) ──
          │
above threshold ──┼── below threshold
 (normal /        │        (microform → lobar → semilobar → alobar)
  carrier)        │
          ▼
      Correlated brain + face midline phenotype

Causal chain (upstream → downstream):

Heterozygous SHH LOF variant
   → reduced SHH ligand production / secretion / lipidation (cholesterol + palmitate)
      → subthreshold Hedgehog signaling in rostroventral forebrain (GD 18–28)
 → failed induction/maintenance of ventral midline (floorplate, notochord)
    → incomplete cleavage of prosencephalon + apoptosis in craniofacial primordia
       → graded midline brain (alobar↔lobar↔microform) & face defects
  → clinical: seizures, developmental delay, dysautonomia,
    hypothalamic-pituitary dysfunction (central DI ~47%)

This model explains the disease's paradoxes: why SHH variants skew mild (ligand haploinsufficiency often leaves signaling nearer threshold than transcription-factor genes SIX3/ZIC2); why mutation-positive relatives can be asymptomatic or high-functioning; and why maternal diabetes so dramatically elevates risk (metabolic disruption pushing signaling below threshold in a genetically susceptible embryo). Pathway: Sonic Hedgehog signaling (KEGG hsa04340; Reactome R-HSA-5358351). SHH is autocatalytically cleaved and dual-lipidated, dispatched by DISP1, carried by SCUBE2, handed via GAS1/CDON/BOC to PTCH1, relieving inhibition of SMO and activating GLI2/GLI3. Suggested GO terms: GO:0007224 (smoothened signaling pathway), GO:0021871 (forebrain regionalization), GO:0021775 (smoothened signaling in ventral spinal cord patterning), GO:0006915 (apoptotic process), GO:0016540 (protein autoprocessing). Suggested CL terms: CL:0000681 (radial glial cell), CL:0011020 (neural progenitor), CL:0000333 (cranial neural crest cell), floor-plate cells. Suggested CHEBI: CHEBI:16113 (cholesterol), CHEBI:15756 (palmitic acid). Suggested UBERON: UBERON:0001890 (forebrain), UBERON:0001898 (hypothalamus), UBERON:0000007 (pituitary), UBERON:0000970 (eye).

Section-by-Section Characterization (Full Template Coverage)

1. Disease Information

SHH-HPE denotes the subset of holoprosencephaly caused by heterozygous SHH variants (HPE type 3), plus its graded continuum from cyclopia/alobar HPE to isolated microforms. Identifiers: OMIM #142945 (HPE3), SHH *600725; MONDO:0016296; ORPHA:2162; ICD-10 Q04.2; ICD-11 LA05.0; MeSH D016142; HGNC:10848; UniProt Q15465; Ensembl ENSG00000164690. Synonyms: Holoprosencephaly type 3; SHH-related HPE; arhinencephaly (older/registry term); microform HPE; cyclopia–cebocephaly–ethmocephaly (severe facial forms). Source type: aggregated disease-level resources (OMIM, Orphanet, HPO) and primary literature/registries (EUROCAT, Texas, Japan) — not individual EHR (PMID: 17274816).

2. Etiology

Primary cause: heterozygous LOF of SHH → haploinsufficiency (PMID: 19186244). Genetic modifiers: GLI2, PTCH1, GAS1, CDON, BOC, DISP1, FGF8, TGIF1, ZIC2, SIX3, TDGF1; combined GAS1+SHH illustrates multiple hits (PMID: 20583177); NODAL/NOTCH/WNT-PCP/FGF/RAS-ERK/cilia/cohesin (PMID: 41102431). Environmental risk: maternal pregestational diabetes, twinning, female predominance (PMID: 29761639); alcohol and aerosol exposure (PMID: 33111505). Protective: preconception glycemic control, adequate maternal cholesterol/nutrition, teratogen avoidance; no validated protective allele. GxE: threshold trait with documented statistical interactions and a cholesterol-dependent mechanistic basis (PMID: 33111505, PMID: 35231446).

3. Phenotypes

Onset is congenital/prenatal; course is static-structural with progressive (epilepsy) or fluctuating (DI, dysautonomia) complications. QoL impact ranges from profound (alobar) to negligible (microform carriers with normal intellect, PMID: 23112757).

4. Genetic / Molecular Information

Causal gene: SHH (7q36.3). Variant types: missense (most common, N-terminal clustering), nonsense/truncating (e.g., p.Tyr175Ter, PMID: 25056824), frameshift, splice, whole-gene/7q36 deletions, and enhancer variants. Truncating → more frank HPE (49% vs 35%, PMID: 22791840). Classification: ACMG/AMP; large VUS burden motivating functional assays (PMID: 32939873). Allele frequency: pathogenic alleles ultra-rare in gnomAD; SHH LOF-constrained. Origin: germline; >70% inherited (PMID: 21940735); germline mosaicism relevant to recurrence. Consequence: loss of function/haploinsufficiency; allele-specific microforms (I111F, PMID: 11471164). Chromosomal: trisomy 13/18, 7q36/13q/2p deletions (PMID: 31886593, PMID: 24764759). Epigenetic: long-range SHH enhancers regulate spatial dosage; HPE-specific methylation data limited (gap).

5. Environmental Information

Maternal pregestational diabetes (hyperglycemic teratogenesis), alcohol, aerosol/hair-spray occupational exposure (PMID: 33111505); retinoic acid, cholesterol-biosynthesis inhibitors, and the classic SHH-antagonist cyclopamine (Veratrum californicum, causing ovine cyclopia). Sterol disruption impairs SHH cholesterol modification (PMID: 35231446). Infectious agents: not a cause — HPE is developmental, not infectious.

6. Mechanism / Pathophysiology

See the Mechanistic Model section above. Cellular processes: impaired ventral neural progenitor specification, altered proliferation/differentiation balance, apoptosis in craniofacial primordia, and cilium-dependent transduction. Protein dysfunction: reduced secreted/processed SHH ligand; lipidation is obligatory (HHAT loss → severe phenotype, PMID: 23055936). Metabolic: cholesterol pivotal for SHH autoprocessing and SMO regulation. No immune involvement; not degenerative — a developmental patterning failure. Human tissue omics are limited (gap).

7. Anatomical Structures Affected

Primary: forebrain/telencephalon and diencephalon (UBERON:0001890, UBERON:0000956, UBERON:0001898), pituitary (UBERON:0000007). Secondary: eyes/orbits (UBERON:0000970), midface/nose, palate, endocrine axis, craniofacial skeleton. Tissue/cell: neuroepithelium, ventral neural progenitors, floor plate, prechordal plate, frontonasal neural crest. Subcellular: primary cilium (GO:0005929), plasma membrane (SMO/PTCH1), ER/Golgi (SHH processing), nucleus (GLI). Laterality: characteristically midline, bilateral/symmetric.

8. Temporal Development

Onset: congenital, 4th gestational week (days 18–28); detectable by first-trimester ultrasound in severe forms (PMID: 35821640). Course: malformation is non-progressive; alobar frequently lethal in utero/neonatally, milder forms chronic lifelong. Critical period: periconceptional–early first trimester is the sole window for primary prevention; no postnatal correction of the malformation is possible.

9. Inheritance and Population

Epidemiology: ~1/16,000 live births; ~1/250 conceptuses; Japan BPR 1.54/10,000 (PMID: 17274816, PMID: 31886593). Inheritance: autosomal dominant, incomplete (developmental, non–age-dependent) penetrance, highly variable expressivity (PMID: 19186244). Recurrence: >70% of SHH variants inherited → substantial recurrence risk and need for cascade testing (PMID: 21940735); germline mosaicism reported. No anticipation (not a repeat disorder); no established founder effect. Demographics: consistent female predominance and over-representation of twinning (PMID: 29761639); severe facial forms reported preferentially in females (PMID: 24764759).

10. Diagnostics

Imaging (cornerstone): first-trimester ultrasound (monoventricle, fused thalami, absent falx) and fetal/postnatal MRI for subtyping (PMID: 42006104). Genetic algorithm: (1) chromosomal microarray + karyotype first; (2) sequencing + dosage of core genes SHH, ZIC2, SIX3, TGIF1 ± expanded HPE panels; (3) WES/WGS for unresolved cases, capturing enhancer/deep-intronic variants (PMID: 41102431); functional zebrafish assays reclassify VUS (PMID: 32939873). Endocrine workup: screen for central DI and anterior pituitary deficiency (PMID: 25056824). Differential: septo-optic dysplasia, agenesis of corpus callosum, hydranencephaly, severe hydrocephalus; syndromic contexts (trisomy 13, SLOS). Screening: prenatal ultrasound; cascade family testing including for microforms (SMMCI, hypotelorism).

11. Outcome / Prognosis

Severity-dependent; ~36% 10-year survival, lowest among rare CAs (PMID: 35351164, PMID: 37868647). Alobar: days–weeks; semilobar: months–years; lobar/MIHV/microform: can reach adulthood. Favorable survival predictors: non-alobar subtype, female sex, atypical (milder) facial features (PMID: 28640243). Survivor morbidity: severe neurodevelopmental disability, epilepsy, endocrinopathy (DI, panhypopituitarism), dysautonomia, feeding failure, spasticity.

12. Treatment

No cure or disease-modifying therapy; supportive, multidisciplinary care (MAXO terms suggested). Antiepileptic drugs for seizures; desmopressin for central DI plus hydrocortisone/levothyroxine/GH/sex-steroid replacement for pituitary deficiency (PMID: 25056824); management of dysautonomia. Surgical: gastrostomy for feeding failure, cleft lip/palate repair, craniofacial reconstruction, CSF shunting if hydrocephalus. Rehabilitative: PT/OT/speech, developmental services. Palliative care and counseling central in severe forms. No approved gene/RNA/cell therapy; HH-pathway agonists remain preclinical (note that HH antagonists vismodegib/sonidegib are approved for HH-driven cancers — the opposite pathway direction).

13. Prevention

Primary: periconceptional glycemic control in diabetic mothers; avoidance of alcohol, retinoids, and sterol-disrupting exposures; adequate maternal nutrition/cholesterol (PMID: 31454511, PMID: 35104296). Secondary: first-trimester ultrasound screening; prenatal molecular testing. Tertiary: proactive treatment of DI, hypopituitarism, seizures, aspiration. Counseling: essential given AD inheritance with low penetrance/variable expressivity; cascade testing, prenatal diagnosis, and PGT-M options — with the caveat that cognitive status cannot identify carriers (PMID: 23112757). Not applicable: immunization (non-infectious).

14. Other Species / Natural Disease

Taxonomy: mouse (NCBI:txid10090), zebrafish (txid7955), sheep (txid9940), human (txid9606). Orthologs (NCBI Gene): human SHH 6469; mouse Shh 20423; zebrafish shha 30269. Natural disease (OMIA): classic ovine cyclopia ("monkey-faced lamb") from Veratrum californicum grazing (cyclopamine, an SMO antagonist) — the discovery that revealed HH-pathway/cholesterol biology; sporadic HPE in dogs, cats, cattle. Comparative biology: deeply conserved midline patterning; zebrafish/mouse mutants recapitulate cyclopia. Transmission: none — non-infectious, non-zoonotic.

15. Model Organisms

Mouse (MGI): Shh knockout — cyclopia, absent ventral neural tube, notochord/floorplate defects (PMID: 8837770); Hhat mutants — acrania-holoprosencephaly-agnathia (PMID: 23055936); Fgf8 hypomorphs — HPE with hypothalamic-pituitary defects (PMID: 21832120). Conditional/knock-in and pathway-gene models available (IMPC/KOMP/MMRRC). Zebrafish (ZFIN): shha CRISPR/Cas9 rescue assay for variant validation (PMID: 32939873). In vitro: HH-reporter lines, iPSC-derived ventral forebrain organoids. Recapitulation: strong for severe (homozygous/null) phenotype; key limitation is that human heterozygous HPE retains a hypoplastic pituitary whereas homozygous animal models lack it entirely (PMID: 20013843); mice usually need homozygous/compound hits, bridged by sensitized backgrounds and gene-environment paradigms. Resources: MGI, IMPC/KOMP, MMRRC, ZFIN, Alliance of Genome Resources, OMIA.

Evidence Base

Limitations and Knowledge Gaps

1. VUS burden: Only a minor fraction of SHH variants are functionally proven pathogenic (PMID: 32939873); most classification relies on segregation and in silico prediction.
2. Penetrance quantification: Incomplete penetrance is well-documented qualitatively but poorly quantified numerically per variant class — a major counseling gap (PMID: 41102431).
3. Modifier attribution: The specific contribution of individual modifier genes/pathways (NODAL, NOTCH, WNT/PCP, cilia, cohesin) to any given patient's phenotype is rarely resolvable (PMID: 41102431).
4. Model dosage mismatch: Null animal models overstate severity relative to typically heterozygous human disease, especially for pituitary presence/absence (PMID: 20013843).
5. Ascertainment/survivor bias: With ~1/250 conceptus loss vs 1/16,000 live births, live-birth cohorts underrepresent the most severe biology.
6. Epidemiologic confounding: Nongenetic risk associations (diabetes, alcohol) are observational; residual confounding and reverse causation remain possible despite consistent replication.
7. Omics gaps: No human HPE-tissue transcriptomic/epigenomic/methylation profiles specific to SHH-HPE were identified; no validated HPE-specific QoL instrument exists.

Proposed Follow-up Experiments / Actions

1. Variant functional atlas: Systematically classify reported SHH missense/truncating variants using the established zebrafish shha rescue assay (PMID: 32939873) plus a mammalian GLI-reporter signaling assay, converting VUS into actionable calls and mapping genotype→signaling→phenotype.
2. Quantitative penetrance modeling: Combine multi-cohort pedigree data (Solomon 2012, Mercier 2011) to estimate variant-class-specific penetrance and expressivity distributions for counseling (PMID: 22791840, PMID: 21940735).
3. GxE mechanistic test: In Shh-heterozygous mice, test whether maternal hyperglycemia and sterol-synthesis inhibitors shift phenotype severity, directly probing the threshold model and cholesterol-dependent lipidation (PMID: 35231446, PMID: 33111505).
4. Modifier screen: CRISPR screen of NODAL/NOTCH/WNT-PCP/FGF/RAS-ERK/cilia/cohesin candidates in a sensitized Shh-heterozygous background to quantify epistatic contributions to threshold crossing (PMID: 41102431).
5. Prospective endocrine surveillance protocol: Standardize screening for central DI and anterior pituitary deficiency in all molecularly confirmed HPE-spectrum patients, given ~47%/53% frequencies (PMID: 25056824).
6. Preconception prevention trial: Evaluate intensified periconceptional glycemic-control programs for HPE risk reduction in diabetic mothers, leveraging the large diabetes effect sizes (PMID: 31454511, PMID: 35104296).

Report compiled from 10 confirmed findings and 52 reviewed papers across 5 investigation iterations. Evidence source types are noted throughout: human clinical cohorts/registries [H], mouse and zebrafish model organisms [M], in vitro/structural biology [V], and computational/epidemiological meta-analyses [C].

Artifacts

• OpenScientist final report
• OpenScientist final report